



IRANIAN JOURNAL OF BLOOD AND CANCER

The Official Journal of

Iranian Pediatric Hematology and Oncology Society (IPHOS)

Volume 8, Number 3, September 2016

ISSN: 2008-4595

انجمن خون و سرطان کودکان ایران
Iranian Pediatric Hematology & Oncology Society

CHAIRMAN

MOHAMMAD SAEID RAHIMINEJAD, MD

EDITOR-IN-CHIEF

HASSAN ABOLGHAEMI, MD

SCIENTIFIC EDITOR

SAMIN ALAVI, MD

EDITORIAL BOARD

Aggarwal Bharat, India

Alebouyeh Mardawij, Iran

Arzanian Mohammad Taghi, Iran

Biondi Andrea, Italy

Cappellini Maria-Domenica, Italy

Faranoush Mohammad, Iran

Ghavamzadeh Ardeshir, Iran

Khaleghnejad Tabari Ahmad, Iran

Kowsari Farid, Iran

Najmabadi Hosein, Iran

Nakagawara Akira, Japan

Oberlin Odile, France

Pedram Mohammad, Iran

Peyvandi Flora, Italy

Ravindranath Yaddanapudi, USA

Rezvan Hourri, Iran

Samiei Farhad, Iran

Schrappé Martin, Germany

Taher Ali, Lebanon

Telfer Paul, UK

Vosough Parvaneh, Iran

Wagner Hans-Peter, Switzerland

Zandian Khodamorad, Iran

"Iranian Journal of Blood and Cancer" is published by "Iranian Pediatric Hematology and Oncology Society (IPHOS)" in collaboration with "Iranian Blood Transfusion Organization (IBTO)"

"IJBC" is approved as an "Academic Research Journal" by Medical Journal Commissions of the "Ministry of Health" and Medical Education of Islamic Republic of Iran".

Iranian Journal of Blood and Cancer is Covered in IranMedex®

Editorial Office

Pediatric Hematology and Oncology Society, 1st floor, NO.63, Shahid Toosi Street, Tohid Square, Tehran, Iran

Postal Code: 1419783311

Tel/Fax: +98(21)66912679

Website: www.ijbc.ir

Email: Info@ijbc.ir

Reviewers

Abolghasemi Hassan	Goudarzipour Kourosh
Aghaeipour Mahnaz	Jamshidi Khodamorad
Alavi Samin	Karimi Gharib
Alilou Sam	Karimijead Mohammad Hassan
Alizadeh Shaban	Kariminejad Roxana
Amin Kafiabad Sedigheh	Kaviani Saeid
Ansari Shahla	Khaleghnejad Tabari Ahmad
Arjmandi Rafsanjani Khadijeh	Keikhaei Bijan
Arzanian Mohammad Taghi	Kompany Farzad
Azarkeivan Azita	Koochakzadeh Leili
Bahoosh Gholamreza	Maghsoudlu Mahtab
Dehghani Fard Ali	Mehrvar Azim
Eghbali Aziz	Najmabadi Hossein
Ehsani Mohammad Ali	Naseripour Masood
Enderami Ehsan	Nazari Shiva
Eshghi Peyman	Rahiminejad Mohammad Saeid
Faranoush Mohammad	Rahimzadeh Nahid
Farshdoosti Majid	Ramyar Asghar
Habibi Roudkenar Mehryar	Roosrokh Mohsen
Hadipour Dehshal Mahmoud	Saki Najmaldin
Haghi Saba Sadat	Saki Nasrin
Hashemieh Mozghan	Shamsian Bibi Shahin
Hedayati Asl Amir Abbas	Seighali Fariba
Honarfar Amir	Sharifi Zohreh
Ghasemi Fariba	Tashvighi Maryam

Aim and Scope

The Iranian Journal of Blood and Cancer (IJBC) is published quarterly in print and online and includes high quality manuscripts including basic and clinical investigations of blood disorders and malignant diseases and covers areas such as diagnosis, treatment, epidemiology, etiology, biology, and molecular aspects as well as clinical genetics of these diseases editor., as they affect children, adolescents, and adults. The IJBC also includes studies on transfusion medicine, hematopoietic stem cell transplantation, immunology, genetics, and gene-therapy. The journal accepts original papers, systematic reviews, case reports, brief reports and letters to the editor, and photo clinics.

The IJBC is being published since 2008 by the Iranian Pediatric Hematology and Oncology Society (IPHOS). The contents of the journal are freely available for readers and researchers and there is no publication or processing fee.

The IJBC has a scientific research rank and is indexed in Directory of Open Access Journals (DOAJ), Islamic World Science Center (ISC), Index COpernicus (IC), and Embase. It is also visible in the following databases: Magiran, IranMedex, ISC, Scientific Information Database (SID), Cambridge Scientific Abstracts (CSA) Academic Search Complete (ASC), Electronic Journals Library (EJB), CINAHL, GEOBASE, CABI, Global Health, Open-J-Gate, Excerpta Medica, and Google Scholar.

All Submission should be sent online via our online submission system. For further inquiries please email the journal directly. The IJBC benefits from editorial freedom. Our editorial policy is consistent with the principles of editorial independence presented by WAME.

<http://www.wame.org/resources/policies#independence>

Instructions to Authors

Submission Process:

Manuscripts should be sent through the on-line submission system. A submission code is allocated to each article as well as a short submission ID and all the future contacts should be based on this code or ID. The articles are primarily evaluated by our internal screeners who check the articles for any methodological flaws, format, and their compliance with the journal's instructions. Through a double-blind review, the articles will be reviewed by at least two external (peer) reviewers. Their comments will be passed to the authors and their responses to the comments along with the reviewers' comments will then be evaluated by the Editor-in-Chief, the Scientific Editor, and a final reviewer who can be a member of the Editorial Board. The final review process will be discussed in regular editorial board sessions and on the basis of the comments, and the journal's scope, the Editors-in-Chief will decide which articles should be published.

Ethical Considerations:

The journal is a member of the Committee on Publication Ethics (COPE). COPE's flowcharts and guidelines are approached in confronting any ethical misbehavior. The Journal also follows the guidelines mentioned in the *Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals* issued by the International Committee of Medical Journal Editors (ICMJE)

(<http://www.icmje.org/#privacy>).

The research that involves human beings (or animals) must adhere to the principles of the Declaration of Helsinki.

(<http://www.wma.net/en/30publications/10policies/b3/index.html>).

- **Informed consent:**

All patients and participants of the research should be thoroughly informed about the aims of the study and any possible side effects of the drugs and intervention. Written informed consent from the participants or their legal guardians is necessary for any such studies. The Journal reserves the right to request the related documents.

- **Authorship:**

Based on the newly released *Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals*, by the ICMJE, "an Author" is generally considered to be someone who meets the following conditions 1, 2, 3, and 4.

1-Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND

2-Drafting the work or revising it critically for important intellectual content; AND

3-Final approval of the version to be published; AND

4-Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

- **Conflict of Interest:**

We request all the authors to inform us about any kinds of "Conflict of Interest" (such as financial, personal, political, or academic) that would potentially affect their judgment. Authors are preferably asked to fill the uniform disclosure form available through:

(http://www.icmje.org/coi_disclosure.pdf)

- **Plagiarism:**

The authors are not allowed to utilize verbatim text of previously published papers or manuscripts submitted elsewhere.

- **Copyright:**

If a manuscript contains any previous published image or text, it is the responsibility of the author to obtain authorization from copyright holders. The author is required to obtain and submit the written original permission letters for all copyrighted material used in his/her manuscripts.

Retraction Policy:

The IJBC uses the COPE flowchart for retraction of a published article

(<http://publicationethics.org/resources/guidelines>)

to determine whether a published article should be retracted.

Author Consent Form:

All authors must sign an Author Consent Form and return this form via Email so that the journal can begin the article's evaluation process. You hereby warrant that "This article is an original work, has not been published before and is not being considered for publication elsewhere in its final form either in printed or electronic form".

Type of Articles:

Original Articles: Should contain title page, abstract, keywords, introduction, materials and methods, results, discussion, conclusion, acknowledgment, references, tables, and figures, enumerated from the title page. The length of the text should be limited to 3000 words excluding the references and abstract.

Case Reports and Brief Reports: Should not exceed 1500 words. Both should include abstract, keywords, introduction, case presentation, discussion, conclusion acknowledgment, and references. Case reports might have 1 to 4 accompanying figures and/or tables but brief reports should not have more than one figure or table. Necessary documentations of the case(s) like pathology and laboratory test reports should be included in the submission package.

Clinical Trials: should contain patients' informed consent and the approval of the ethics committee of the corresponding institution.

Review Articles: might be requested by the editor, but IJBC will also accept submitted reviews. Both solicited and unsolicited review articles are subjected to editorial review like the original papers.

Letters to the Editor: IJBC accepts letters to the editor. Letters should be less than 500 words. Letters might discuss articles published in the journal during the previous six months or other important aspects related to the field of hematology. Letters will undergo peer-review processing and will be edited for clarity.

Photo clinics: Figures that convey a significant medical point can also be accepted. Photo clinics should contain one or two high quality figures and a description of the figure no more than 500 words. 24- references should be included.

Paper Preparations:

Cover letter should contain a statement that you will not resubmit your article to another journal until the reviewing process will be completed. Also please indicate whether the authors have published or submitted any related papers from the same study.

Title Page of the article should include 1) the title of the article; 2) authors' names; 3) name of the institution where the work was done; 4) running title (short form of the main title presented on the top of pages); and 5) complete mailing address, telephone/fax numbers, and email address of the corresponding author. This page is unnumbered.

Abstract should be structured for original articles providing background/objective for the study, methods, results, and conclusion. It should not exceed 250 words altogether. Number this page as page 1.

Abstracts of other types of contributions should be non-structured providing the essential information.

When abstracting a review article a concise summary of the salient points should be addressed.

Preferably, abbreviations should not be mentioned in the abstract.

Keywords are used for indexing purposes; each article should provide three to five keywords selected from the Medical Subject Headings (MeSH).

<http://www.nlm.nih.gov/mesh/>

Introduction should provide a context or background and specifies the purpose or research objective of the study or observation.

Method must indicate clearly the steps taken to acquire the information. Be sure that it includes only information that was available at the time the plan or protocol for the study was written. It should be detailed (including: controls, inclusion and exclusion criteria, etc) and may be separated into subsections. Repeating the details of standard techniques is best avoided.

For reports of randomized controlled trials, authors should refer to the CONSORT statement (<http://www.consort-statement.org/>). All randomized clinical trials should be registered in any international RCT registration centers approved by the WHO. For research conducted in Iran, it is advised to register at IRCT(www.irct.ir).

Reporting guidelines such as STROBE, STARD, and PRISMA would help you to produce high quality research and to provide all required information and evidence for related methodology. EQUATOR Network website would help you in using these guidelines.

The software used for statistical analysis and description of the actual method should be mentioned.

Results should be presented in chronological sequence in the text, table, and illustration. Organize the results according to their importance. They should result from your own study.

Tables and illustrations must be cited in order which they appear in the text; using Arabic numerals. Tables should be simple and should not duplicate information in the text of the paper. Figures should be provided only if they improve the article. For radiographic films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send the high resolution figures in jpeg or bitmap format. Color photographs, if found to improve the article, would be published at no extra-charge at the print version of the journal. Type or print out legends for illustrations on a separate page, and explain the internal scale and identify the method of staining in photomicrographs.

Discussion should emphasize the new and important aspects of the study and the conclusions that follow them. Possible mechanisms or explanations for these findings should be explored. The limitations of the study and the implications of the findings for future research or clinical practice should be explored.

Conclusion should state the final result that the author(s) has (have) reached. The results of other studies should not be stated in this section.

Supplementary Materials such as movie clips, questionnaires, etc may be published on the online version of the journal.

Any technical help, general, financial, and material support or contributions that need acknowledging but do not justify authorship, can be cited at the end of the text as **Acknowledgments**.

References should be compiled numerically according to the order of citation in the text in the Vancouver style. The numbers of references should not preferably exceed 40 for original articles, 15 for brief, and 8 for case reports.

For the references credited to more than 6 authors please provide the name of the first six authors and represent the rest authors by the phrase “et al.”

For various references please refer to “the NLM style guide for authors, editors, and publishers”. (<http://www.ncbi.nlm.nih.gov/books/NBK7256/>)

Listed below are sample references.

Journal Article:

- Gaydoss A, Duysen E, Li Y, Gilman V, Kabanov A, Lockridge O, et al. Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. *Chem Biol Interact.* 2010;187:295-8. doi: 10.1016/j.cbi.2010.01.005. PubMed PMID: 20060815; PubMed Central PMCID: PMC2998607.
- Javan S, Tabesh M. Action of carbon dioxide on pulmonary vasoconstriction. *J Appl Physiol.* In press 2005

Complete Book:

- Guyton AC: *Textbook of Medical Physiology.* 8th ed. Philadelphia, PA, Saunders, 1996.

Chapter in Book:

- Young VR. The role of skeletal muscle in the regulation of protein metabolism. In Munro HN, editor: *Mammalian protein metabolism.* Vol 4. San Diego; Academic; 1970. p. 585-674.

Language and Style:

Contributions should be in either American or British English language. The text must be clear and concise, conforming to accepted standards of English style and usage. Non-native English speakers may be advised to seek professional help with the language.

All materials should be typed in double line spacing numbered pages. Abbreviations should be standard and used just in necessary cases, after complete explanations in the first usage. The editorial office reserves the right to edit the submitted manuscripts in order to comply with the journal's style. In any case, the authors are responsible for the published material.

Correction of Errata:

The journal will publish an erratum when a factual error in a published item has been documented.

For further information please contact the Editorial Office:

Tel: +98 21 66912676

Email: ijbc_iphos@yahoo.com

Website: www.ijbc.ir

Original Articles

Platelet Factor 3 Based-clotting Time Assay as a Quality Marker for Long-term Storage of Platelet Concentrates.....**63**

Saleh Nasiri, Fatemeh Abbasi

The Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study.....**68**

Robab Sheikhpour, Fatemeh Pourhosseini

The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran.....**72**

Behnaz Habibpanah, Zahra Tara, Fatemeh Malek, Rezvan Ardeshiri, Tahmineh Salimi, Azam Saafi, Belgheis Fasih, Mohammad Reza Managhchi

Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients.....**75**

Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi

Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients.....**80**

Ali Ghasemi, Sadegh Abbasian, Kazem Ghaffari, Zeynal Salmanpour

Case Report

Lineage Switch in Childhood Leukemia: A Case Report and Review of Literature.....**86**

Shiva Nazari, Fatemeh Malek, Navid Zavvar

Letters to Editor

Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia.....**88**

Babak Abdolkarim

Photo Clinic

Portal Vein Thrombosis Following Splenectomy in β -thalassemia Major.....**90**

Sara Sadeghi, Ahmad Mohammadi Ashiani, Mitra Khalili



ORIGINAL ARTICLE

Platelet Factor 3 Based-clotting Time Assay as a Quality Marker for Long-term Storage of Platelet Concentrates

Saleh Nasiri^{1*}, Fatemeh Abbasi²

¹Department of Biotechnology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

²Department of Production, Tehran Blood transfusion Center, Tehran, Iran

ARTICLE INFO

Article History:

Received: 13.05.2016

Accepted: 02.07.2016

Keywords:

Platelet concentrate

Platelet factor 3

pH

LDH

MPV

Platelet storage lesions

Quality marker

Platelet recovery

*Corresponding author:

Saleh Nasiri

Address: Department of Biotechnology,

Blood Transfusion Research Center,

High Institute for Research and

Education in Transfusion Medicine,

IBTO bldg., Hemmat Exp. Way, Next

to the Milad Tower, P.O. Box: 14665-

1157, Tehran, Iran

Tel: +98 21 88625471

Fax: +98 21 88601574

Email: salehnasiri2012@gmail.com

ABSTRACT

Background: Platelets rapidly lose their qualities usually after 5 day of storage. Different standard methods have been recommended to check the quality of platelets during storage which some of them show better correlation with other quality markers during storage. The purpose of this study was to demonstrate if platelet factor 3 (PF3) assay could be an indicator of storage lesion and provide a significant correlation with other quality markers during long-term storage of platelet concentrates (PC) up to 11 days.

Methods: Twelve random units of PC were placed in a standard platelet incubator under continuous agitation at 22-24°C for eleven days. Samples were taken on days 1, 3, 5, 8 and 11. Parameters such as pH, glucose, lactate dehydrogenase (LDH), platelet count of the bags, mean platelet volume (MPV) and platelet distribution width (PDW) and PF3 were measured. The correlation coefficient of PF3 and pH with the abovementioned parameters was evaluated.

Results: The mean percentage of changes for PF3, pH, glucose, LDH, platelet count, MPV and PDW on day 11 compared to the first day were found to be 61, 15, 52, 440, 19, 18 and 39%, respectively. After LDH, PF3 had the highest change relative to the other markers. PF3 demonstrated better correlation with glucose, platelet count, MPV and PDW compared with pH during long-term PC storage.

Conclusion: Platelet factor 3 based-clotting time assay could be a potential candidate for monitoring the quality of PC due to apparent trend of its changes during storage with better correlation between the quality markers.

Please cite this article as: Nasiri S, Abbasi F. Platelet Factor 3 Based-clotting Time Assay as a Quality Marker for Long-term Storage of Platelet Concentrates. IJBC 2016; 8(3): 63-67.

Introduction

Platelet storage lesions (PSL) are well-known events during preparation and storage of platelet concentrates (PC). Such changes are associated with decreased hemostatic function of platelets after transfusion and with poor post-transfusion recovery.¹ Various factors are responsible for the PSL and hence poor quality of PCs. There are numerous standards to check the quality of platelets during storage that have been published by various authorities, such as the European Council and American

Association of Blood Banks (AABB). Various tests are available varying from the simplest tests such as swirling to complex platelet function tests. Though swirling is a simple and non-invasive test, it is prone to observer bias.^{2,3} The swirling was observed in 94% of cases with a pH value in the range of 6.7-7.5.² This pH range is associated with adequate in vivo survival.^{4,5} Unfortunately, in practice there is no single laboratory test than can accurately predict the efficacy of a platelet transfusion and in other words its appropriate recovery following transfusion.⁶ Previous

studies have reported that pH, as a major quality marker, shows the highest correlations with recovery and survival of platelets in healthy subjects.^{7,8}

Platelet factor 3 (PF3), as a phospholipid lipoprotein blood coagulation factor derived from platelets acts with certain plasma thromboplastin factors to convert prothrombin to thrombin. The PF3 assay relies on the principle that incubation of platelet-rich plasma (PRP) with kaolin activates the procoagulant activity of platelets, resulting in a progressive shortening of both the recalcification time and Russell viper venom time and can be used specifically for assessing platelet procoagulant activity.^{9,10} This novel test may also be used to monitor procoagulant activity of platelet membrane in platelet substitutes such as lyophilized intact platelets¹¹ or lyophilized infusible platelet membranes¹²⁻¹⁶ in the future as well. We aimed to assess if PF3 assay indicates higher correlation compared with other quality markers such as pH during long-term storage of platelet concentrates up to 11 days and if it could be applied to monitor quality control of platelet concentrates in the future.

Materials and Methods

Study Design

In this study, 12 PCs were collected from healthy volunteers in Tehran Blood Transfusion Center as a routine procedure according to the platelet rich plasma method from whole blood with soft and hard spin centrifugation steps, respectively. After collection, standard PCs were kept undisturbed for one hour. The sterility test were performed to show no bacterial contamination of PCs and then they were placed in a standard platelet incubator with shaker (Danesh Pajoohesh Fajr Co, Iran) under continuous agitation at 22-24°C for eleven days.

Sampling

Sampling was done aseptically with a large bore needle.

Three milliliter samples of each PC unit were taken on 1, 3, 5, 8 and 11 days and the following tests were performed by biochemical and hematological analyzers.

Biochemical and Hematological Tests

Parameters such as pH, glucose as a main catabolic cell pathway (glycolysis), lactate dehydrogenase (LDH) as an enzyme marker of cell viability, pre-donation platelet count of donor, total platelet count of the bags, platelet yield extraction, mean platelet volume (MPV) and platelet distribution width (PDW) as morphostructural platelet indices were measured.

PF3 Assay

PF3 as a major platelet function based-clotting time assay was performed on the samples during storage of platelet concentrates according to the kaolin clotting time method.⁹ Fresh platelets and physiological normal saline were used as positive and negative controls, respectively. The clotting time was converted to percent of activity by use of a standard curve.

Statistical Analysis

True values was converted to mean percentage values with regard to initial value of 100 percent on day 1 and correlation coefficient (r) analysis was performed to compare the ability of PF3 and pH as quality markers during a 11-days storage period.

Results

The relevant data of twelve PCs in terms of quality control parameters of platelets such as pH, glucose, LDH, platelet count, MPV and PDW during eleven days storage are reported as mean percentage changes in table 1. Mean percentage platelet yield extraction of PCs during storage up to eleven days was shown in table 2. During storage, metabolic activity of platelets continued

Table 1: Mean percentage changes in the quality control markers of twelve platelet concentrates during standard storage up to eleven days

Day of storage	PF3	Glucose	pH	LDH	Platelet Count	MPV	PDW
1	100* (0)**	100 (0)	100 (0)	100 (0)	100 (0)	100 (0)	100 (0)
3	90*** (10)	90 (10)	99 (1)	171 (71)	98 (2)	108 (8)	113 (13)
5	77 (23)	80 (20)	98 (2)	253 (153)	92 (8)	110 (10)	115 (15)
8	60 (40)	65 (35)	93 (7)	377 (277)	85 (15)	114 (14)	123 (23)
11	39 (61)	48 (52)	85 (15)	540 (440)	81 (19)	118 (18)	139 (39)

*Percent of initial value was assumed 100 on day 1 for all quality control markers; **Data shows mean percentage of increase or decrease relative to initial value of 100 percent; ***Mean Percentage: Each true value was converted into percent with regarding to initial value of 100 percent on day 1

Table 2: Mean percent of platelet yield extraction* of twelve platelet concentrates (PCs) during standard storage up to eleven days

Day of storage	Total platelet count of PCs/bag ($\times 10^4$)	Platelet yield extraction/bag (%)	Platelet yield extraction/bag** (%)
1	6862002	61	100
3	6711816	60	98 (2)
5	6309816	56	92 (8)
8	5803638	52	85 (15)
11	5544546	49	81 (19)

*Total pre donation platelet count/bag was calculated as 11149184×10^4 ; **Percent of initial value of platelet yield was assumed 100 on day 1 for PCs

leading to glucose consumption that led to a trend of decreasing pH due to glycolytic energy generation and lactate production. Better trend was observed in LDH production, PF3 activity decline, glucose consumption, increasing of PDW and MPV, platelet count depletion and decreasing pH, respectively (figure 1). Our results showed that platelet counts per bag do decrease slowly during storage, albeit with the acceptable platelet count ($>55 \times 10^9/\text{bag}$) according to the conventional standards even at the end of the storage (table 2).

The coefficient correlation of pH and PF3 versus other quality markers was calculated in table 3. Strong correlation was observed between pH and LDH, PF3, glucose, PDW, platelet count and MPV, respectively. High correlation was also observed between PF3 and glucose, platelet count, PDW, pH, MPV and LDH, respectively.

Discussion

We found that PF3 could be altered as a result of platelet storage and hence be associated with storage lesions during long-term storage of PCs similar to other quality parameters such as pH, glucose, LDH, platelet count,

MPV and PDW. Similar results have been reported by previous studies for pH,^{7,17-26} glucose,^{7,19,20,22-26} LDH,^{20,22,23,25} platelet count,^{7,20,21,23-26} MPV^{20,21,23} and PDW²¹ of PCs that confirm their roles in monitoring the quality of platelets during storage. Minor differences in these studies may be related to the preparation method of the platelets,^{27,28} the plastic material of the storage bag,⁴ the ability of bags to exchange gas across its surface,⁵ storage temperature,^{27,29} the type of anticoagulant used, the platelet concentration in the bag and the agitation.²⁷

On the other hand, PF3 which has phospholipid procoagulant activity of platelet membrane, as a clotting time assay, has not been used as a quality marker in the literature. Chao³⁰ used PF3 assay to show the functional properties of infusible platelet membrane product. Recently, studies have shown that flow cytometric analysis of CD41/CD61 and CD42b platelet receptors with PF3 based-clotting time assay may also show the status of platelet concentrates during storage.³¹

Accordingly, Bode³² analyzed platelet factor 3 in platelet concentrates during PC storage and demonstrated higher PF3 and LDH activity that were significantly correlated




Figure 1: Trend in pH, glucose, platelet count, LDH, PF3, MPV and PDW. Each point represents the mean percentage value of twelve platelet concentrates stored in standard condition up to eleven days with regarding to initial value of 100 percent on day 1.

Table 3: Correlation coefficient values of pH and PF3 with other platelet quality control markers during 11 days storage of platelet concentrates

Parameter	Correlation coefficient of pH (r)	Correlation coefficient of PF3 (r)
Glucose	0.961	-0.999
LDH	-0.977	0.929
Plt. Count	0.934	0.982
MPV	-0.868	0.958
PDW	-0.959	0.978
PF3	-0.969	1.000
pH	1.000	-0.969

together only in standard, manual PC. Measurement of cytoplasmic leakage of LDH may also be used as a quality parameter and reflects platelet membrane damage. LDH has been shown to correlate to platelet survival ($r=0.64$).³³ In our study, LDH and PF3 had trends showing storage lesions more relevant in comparison with other markers (Figure 1).

Our results demonstrated that pH declines steadily from day 1 (7.78) to day 5 (7.61) of storage, but sharper decline was observed between days 5 to 11 of storage with the mean pH of 6.61 at the end of storage which reflects better preservation of platelets during long-term storage with only 15 percent decrease in the pH. There was not an increase in pH between the first and third days of storage as reported by Dekkers³³ which may reflect the temporary changes in gas concentrations. The pH is an important marker for the quality of PCs *in vitro* since at values below 6.8, platelets become spherical; this change in shape becomes irreversible when the pH drops below 6.2. Platelet metabolism ceases completely when pH values drop below 6.0.³⁴

Conclusion

It may be concluded that platelet factor 3 based-clotting time assay can be a potential candidate for monitoring the quality of PCs due to the observed trend of its changes during storage. In comparison with pH, this test may also show better correlation with the other quality markers. However, further investigations are required to find the efficacy and precision of PF3 as quality marker and also look for other markers that help predict precisely status of PCs during storage.

Conflict of Interest: None declared.

References

1. Holme S. Storage and quality assessment of platelets. *Vox Sang*. 1998; 74 Suppl 2:207-16. doi: 10.1111/j.1423-0410.1998.tb05422.x. PubMed PMID: 9704447.
2. Bertolini F, Murphy S. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical excellence for safer transfusion (BEST) working party of the international society of blood transfusion. *Transfusion*. 1996; 36:128-32. doi: 10.1046/j.1537-2995.1996.36296181924.x. PubMed PMID: 8614962.
3. Tynngård N. Preparation, storage and quality control of platelet concentrates. *Transfus Apher Sci*. 2009; 41:97-104. doi: 10.1016/j.transci.2009.07.001. PubMed PMID: 19699153.
4. Murphy S, Sayar SN, Gardner FH. Storage of platelet concentrates at 22°C. *Blood*. 1970; 35:549-57. *Blood*. 2016; 128(9):1155. doi: 10.1182/blood-2016-07-729087. PubMed PMID: 27587860.
5. Murphy S, Gardner FH. Platelet storage at 22 °C: role of gas transport across plastic containers in maintenance of viability. *Blood*. 1975; 46(2):209-18. PubMed PMID: 237590.
6. Pietersz RN, Engelfriet CP, Reesink HW, Georgsen J, Taaning E, Kekomäki R, et al. Evaluation of stored platelets. *Vox Sang*. 2004; 86(3):203-23. doi: 10.1111/j.0042-9007.2004.t01-1-00409.x. PubMed PMID: 15078259.
7. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P. Correlation of *in vitro* platelet quality measurements with *in vivo* platelet viability in human subjects. *Vox Sang*. 2006; 90:279-85. doi: 10.1111/j.1423-0410.2006.00761.x. PubMed PMID: 16635070.
8. Filip DJ, Eckstein JD, Sibley CA. The effect of platelet concentrate storage temperature on adenine nucleotide metabolism. *Blood*. 1975; 45(6):749-56. PubMed PMID: 236055.
9. Margolis J. The kaolin clotting time, a rapid one-stage method for diagnosis of coagulation defects. *J Clin Path*. 1958; 11(5):406-9. PubMed PMID: 13575555. PubMed Central PMCID: PMC479806.
10. Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. *J Thromb Haemost*. 2011; 9(10): 1883-91. doi: 10.1111/j.1538-7836.2011.04478.x. PubMed PMID: 21958383.
11. Nasiri S, Khosroshahi BN. Lyophilization of human platelet and study of its aggregability. *IJDD*. 2012; 3: 241-4.
12. Nasiri S, Heidari M, Rivandi S. Evaluation of hemostatic effectiveness of infusible platelet membrane in rabbits as a potential substitute for platelet transfusion. *JDDT*. 2012; 2(5):1-3.
13. Nasiri S, Heidari M, Rivandi S. Infusible platelet membranes improve hemostasis in thrombocytopenic rabbits: studies with two different injection doses. *IJPSR*. 2012; 3:4895-8. doi: 10.13040/IJPSR.0975-8232.3(12).4895-98.
14. Nasiri S. Platelet membranes versus intact platelets: Feasibility as a potential platelet substitute. *WJPPS*. 2013; 2:763-81.
15. Nasiri S. Infusible platelet membrane as a platelet substitute for transfusion: an overview. *Blood Transfus*. 2013; 11(3):337-42. doi: 10.2450/2013.0209-12. PubMed Central PMCID: PMC3729122.
16. Nasiri S, Mousavi Hosseini K. Infusible platelet membrane versus conventional platelet concentrate: benefits and disadvantages. *IJBC*. 2014;6(2):87-93.
17. Gkoumassi E, Klein-Bosgoed C, Dijkstra-Tiekstra MJ, de Korte D, de Wildt-Eggen J. Noninvasive pH monitoring of platelet concentrates: a large field test. *Transfusion*. 2013; 53(10):2287-92. doi: 10.1111/trf.12099. 23362882. PubMed PMID: 23362882.
18. Dumont LJ, AuBuchon JP, Gulliksson H, Slichter SJ, Elfath MD, Holme S, et al. *In vitro* pH effects on *in vivo* recovery and survival of platelets: an analysis by the best collaborative. *Transfusion*. 2006; 46(8):1300-5. doi: 10.1111/j.1537-2995.2006.00895.x.
19. Murphy S, Gardner FH. Platelet storage at 22 °C; metabolic, morphologic and functional studies. *J Clin Invest*. 1971; 50(2):370-7. doi: 10.1172/JCI106504. PubMed PMID: 5540174. PubMed Central PMCID:

- PMC291933.
20. van der Meer PF, Pietersz RN, Reesink HW. Storage of platelets in additive solution for up to 12 days with maintenance of good in-vitro quality. *Transfusion*. 2004; 44(8):1204-11. doi: 10.1111/j.1537-2995.2004.04010.x. PubMed PMID: 15265125.
 21. Singh H, Chaudhary R, Ray V. Platelet indices as quality markers of platelet concentrates during storage. *Clin Lab Haem*. 2003; 25(5):307-10. doi: 10.1046/j.1365-2257.2003.00539.x. PubMed PMID: 12974721.
 22. Izadpanahi HA, Yari F, Khorramizadeh MR, Maghsudlu M. Evaluation of biochemical parameters of platelet concentrates stored in plasma or in a platelet additive solution (Composol). *ijpho*. 2011; 1(3): 83-9.
 23. Amorini AM, Tuttobene M, Lazzarino G, Denti G. Evaluation of biochemical parameters in platelet concentrates stored in glucose solution. *Blood Transfus*. 2007; 5(1):24-32. doi: 10.2450/2007.0019-06. PubMed PMID: 19204748. PubMed Central PMCID: PMC2535872.
 24. Slichter SJ, Bolgiano D, Jones MK, Christoffel T, Corson J, Rose L, et al. Viability and function of 8-day-stored apheresis platelets. *Transfusion*. 2006; 46(10):1763-9. doi: 10.1111/j.1537-2995.2006.00970.x. PubMed PMID: 17002633.
 25. Cookson P, Sutherland J, Turner C, Bashir S, Wiltshire M, Hancock V, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. *Transfus Med*. 2010; 20(6):392-402. doi: 10.1111/j.13653148.2010.01034.x. PubMed PMID: 20738829.
 26. VandenBroeke T, Dumont LJ, Hunter S, Nixon J, Murphy S, Roger J, et al. Platelet storage solution affects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. *Vox Sang*. 2004; 86(3):183-8. doi: 10.1111/j.0042-9007.2004.00412.x. PubMed PMID: 15078253.
 27. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. II. Storage variables influencing platelet viability and function. *Br J Haematol*. 1976; 34:403-19. doi: 10.1111/j.1365-2141.1976.tb03587.x. PubMed PMID: 10956.
 28. Nasiri S. Conversion from platelet-rich plasma platelet production to buffy coat platelet component production: benefits and limitations. *IJBC*. 2014; 6(4):188-207.
 29. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability-deleterious effect of refrigerated storage. *N Engl J Med*. 1969; 280(20):1094-8. doi: 10.1056/NEJM196905152802004. PubMed PMID: 5778424.
 30. Chao FC, Kim BK, Houranieh AM, Liang FH, Konrad MW, Swisher SN, et al. Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. *Transfusion*. 1996; 36(6):536-42. doi: 10.1046/j.15372995.1996.36696269513.x. PubMed PMID: 8669086.
 31. Nasiri S, Vaeli Sh. Flow cytometric measurement of CD41/CD61 and CD42b platelet receptors and clotting assay of platelet factor 3 during long term-storage of platelet concentrates. *IJBC*. 2015; 7(2):61-5.
 32. Bode AP, Miller DT. Analysis of platelet factor 3 in platelet concentrates stored for transfusion. *Vox Sang*. 1986; 51(4):299-305. doi: 10.1111/j.1423-0410.1986.tb01972.x. PubMed PMID: 3798864.
 33. Dekkers DW, De Cuyper IM, van der Meer PF, Verhoeven AJ, de Korte D. Influence of pH on stored human platelets. *Transfusion*. 2007; 47(10):1889-95. doi: 10.1111/j.1537-2995.2007.01412.x. PubMed PMID: 17880616.
 34. Baker JM, Candy DJ, Hawker RJ. Influences of pH on human platelet metabolism. *Platelets*. 2001; 12(6):333-42. doi: 10.1080/09537100120078412. PubMed PMID: 11672472.



ORIGINAL ARTICLE

The Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study

Robab Sheikhpour^{1*}, Fatemeh Pourhosseini²

¹Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Science, Yazd, Iran

²Kerman Medical University, Kerman, Iran

ARTICLE INFO

Article History:

Received: 20.06.2016

Accepted: 10.08.2016

Keywords:

Diffuse large B cell lymphoma

CD20

CD45

CD3

CD2

*Corresponding author:

Robab Sheikhpour,
Hematology and Oncology Research
Center, Shahid Sadoughi University of
Medical Science, Yazd, Iran
Email: robab.sheikhpour@iauyazd.
ac.ir

ABSTRACT

Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL.

Methods: In the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (2010–2013), central Iran. Immunohistochemical method was used for detecting biomarkers such as CD2, CD3, CD20 and CD45.

Result: In this study, 54.5% of the patients were men and 45.5% were women. Most of the patients were 40-50 years old. Moreover, 10 (22.7%) patients had lymph node metastasis and 6 (13.6%) patients had stomach involvement. Positive expression of CD45 and CD20 biomarkers were expressed in 100% and 97.7% of the patients. Positive expression of CD3 and CD2 was expressed in 40.9% and 81.8% of the patients, respectively. C-expression of CD45 and CD20 biomarkers was seen in 43 patients. Moreover, there was no relation between biomarkers and sex and age ($P>0.05$).

Conclusion: The result of this study showed that high number of CD45 and CD20 have been seen in Iran's population. Moreover expression of CD20 and CD45 is different as compared with other populations. It seems that these differences can be due to ethnic groups and nature of malignant cells.

Please cite this article as: Sheikhpour R, Pourhosseini F. The Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study. IJBC 2016; 8(3): 68-71.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes.^{1,2} It is known as a heterogeneous disease³ with variable therapeutic responses and alternative therapies.⁴ The causes of diffuse large B cell lymphoma are not well understood yet.⁵ Following nodular lymphocyte predominant HL, diffuse large B-cell lymphoma (DLBCL) can be observed as one of the most common lymphoid malignancy in adults diagnosed on basis of morphology and immunophenotype.⁶ DLBCL accounts for 30–40%

of adult non-Hodgkin lymphomas.⁷ The peak occurrence of diffuse large B-cell lymphoma (DLBCL) arises in the seventh decade of life.⁸ The first sign of this disease is rapidly growing mass, fever, weight loss, and night sweats.⁹ Diffuse large beta cell lymphoma disorder manufactured of a clinically and pathologically heterogeneous group of lymphoproliferative malignancies, most of which are B-cell origin.⁸ Morphological and immunophenotypical evaluation of the biopsy specimens can help to diagnosis of DLBCL.¹⁰

Diffuse large B cell lymphoma includes three variants

in term of morphology. Centroblastic, Immunoblastic^{5,11} and anaplastic. Most DLBCL cases are centroblastic.⁵ Each has a diverse clinical presentation and prognosis. However, the usual treatment for each of these is chemotherapy, often in combination with an antibody targeted at the tumor cells.¹² The disease is treatable in most patients, but fewer than half of them attain a durable remission.¹ CD3 is a marker for T cells and natural killer cells.¹³ It is specific for T-cell derivation. CD2 is also expressed by T and natural killer (NK) cells and has been reported in T/NK cell lineage neoplasms as well as in immature B-lymphoblastic and myeloid leukemias.¹⁴ CD45 (lymphocyte common antigen) is a receptor-linked protein tyrosine phosphatase¹⁵ and expressed on all leucocytes. It plays a significant role in the action of these cells.¹⁶ CD20 is an activated glycosylated phosphoprotein. It is expressed on the surface of B cells beginning at the pro-B phase (CD45R+, CD117+).¹⁷ We aimed to evaluate CD markers such as CD45, CD20, CD3 and CD2 in patients with diffuse large B cell lymphoma in Yazd city, central Iran.

Materials and Methods

In this study, 44 patients were enrolled from Shaheed Sadoghi Hospital, Yazd, central Iran during 2010-2013. The specimens were conserved in formalin. Following fixation, the specimens were embedded on wax paraffin and sliced to 4 μ m in thickness for staining. The hematoxylin and eosin staining method was used to stain the tissue sections. In immunohistochemical method, Endogenous peroxidase was blocked by 3% hydrogen peroxide in methanol for 10 minutes at room temperature. Heat-induced epitope retrieval was done by heating these

sections in citrate buffer (pH 9.0) using the microwave technique. After cooling, the sections were exposed with primary antibody (table 1).

Then, the specimens were exposed to Horseradish peroxidase rabbit anti-mouse IgG for 30 min and incubated with 3,3-diamino-benzidine tetrahydrochloride. The sections were counterstained with hematoxylin and rinsed in tap water, followed by immersing in graded alcohol, xylene and finally mount. Negative control was done by displacement of the primary antibody with fetal bovine serum in each series.

Result

In our study, the mean \pm SD age of the patients was 55.8 \pm 9.5 years. 27 (61.2%) out of 44 patients were younger than 60 years old. 54.5% of the patients were men. 10 (22.7%) patients had lymph node metastasis. Table 2 shows the primary tissue involvement.

In this study CD45 was expressed in 100%, CD20 in 97.7%, CD3 in 40.9%, and CD2 in 81.8, respectively. Table 3 shows expression of these biomarkers in the patients.

Table 4 shows co-expression of Biomarkers. No relation between percentage of expression of biomarkers with sex was observed (P>0.05).

Discussion

In the present study, immunohistochemical staining of the specimens with DLBCL were positive for CD45 and CD20 in almost all of the patients and less than half expressed CD3 and CD2. Asano and colleagues reported negativity for CD20 and CD3 in their patients with DLBCL.¹⁸ Kevin and co-workers reported that some cases of DLBCL with an anaplastic morphology may be rich in

Table 1: Antibodies used for immunohistochemical staining of the tumor markers in patients with DLBCL

Antibody	Isotype	Dilution	Source
CD2	Monoclonal mouse antibody AB75	Ready to use	Dako
CD20	Monoclonal mouse antibody L26	Ready to use	Dako
CD3	Polyclonol rabbit	Ready to use	Dako
CD45	Monoclonal mouse 2B11+PD7/26	Ready to use	Dako

Table 2: Primary tissue involvement in patients with DLBCL

Primary tissue involvement	Number/Percent
Stomach	6 (13.6%)
Cervix	2 (4.5%)
Thyroid	3 (6.8%)
Breast	1 (2.2%)
Bone marrow	2 (4.5%)
Pelvis	2 (4.5%)
Skin	2 (4.5%)
Colon	2 (4.5%)
Kidney	3 (6.8%)
Testis	2 (4.5%)
Neck	3 (6.8%)
Lymph node	10 (22.7%)
Tonsil	4 (9.09%)
Mesentery	2 (4.5%)
Total	44 (100%)

Table 3: Positive expression of biomarkers in patients with DLBCL

Positive expression of biomarkers	Number/Percent
CD45	44 (100%)
CD20	43 (97.7%)
CD2	36 (81.8%)
CD3	18 (40.9%)

Table 4: Co-expression of biomarkers in patients with DLBCL

Co-expression of biomarkers	Number	Percent
CD20, CD45	43	97.7
CD20, CD2	36	81.8
CD20, CD3	18	40.9

Reed-Sternberg like cells and thus simulate lymphocyte-depleted classical Hodgkin lymphoma. However, in contrast to Hodgkin lymphoma, these neoplastic cells were uniformly positive for both CD20 and CD79a antigens and were negative for CD15. Therefore, they reported that the majority (65-85%) of the cases of DLBCL in their study were of B-cell type.¹¹

Stein et. al reported that CD30 which was constantly expressed in Reed-Sternberg cells, also is expressed by a subset of DLBCL patients.¹⁹ In another study, aberrant expression of a single T-cell-associated antigen (CD5) on specimens of DLBCLs was reported.²⁰ The researchers also reported aberrant co-expression of 2 T-cell-associated antigens; CD2 and CD7 in patients with diffuse DLBCL. In a study by Toyama et. al, flowcytometric immunophenotyping of the DLBCL cases were negative for CD2, CD3 and positive for CD20.²¹ Asano et. al in another study reported that CD30 and CD45 were positive in DLBCL (anaplastic variant), but negative for CD3, CD10, CD20, CD15.¹⁸

Conclusion

The result of this study showed high percentage of CD45 and CD20 seen in Iran's positivity in Iranian patients with lymphoma. It seems that these differences could be due to ethnic factors.

Conflict of Interest: None declared.

References

- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*. 2000; 403(6769):503-11. doi: 10.1038/35000501. PubMed PMID: 10676951.
- Damm JK, Gordon S, Ehinger M, Jerkeman M, Gullberg U, Hultquist A, et al. Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. *Exp Hematol Oncol*. 2015; 4:4. doi: 10.1186/2162-3619-4-4. PubMed PMID: 25973343. PubMed Central PMCID: PMC4429466.
- Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood*. 2005; 105(5):1851-61. doi: 10.1182/blood-2004-07-2947. PubMed PMID: 15550490.
- Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. *Br J Haematol*. 2014; 167(5):608-17. doi: 10.1111/bjh.13085. PubMed PMID: 25135752.
- Swerdlow SH, Campo E, Jaffe ES, Pileri SA, Stein H, Thiele J, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. World Health Organization, 2008.
- Javier G, Ferres R. Large B cell diffuse lymphoma. *Orphanet Encyclopedia*. 2004; 1-5
- Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. *Nat Med*. 2002; 8(1): 68-75. doi: 10.1038/nm0102-68. PubMed PMID: 11786909.
- Cultrera JL, Dalia SM. Diffuse large B-Cell lymphoma: Current strategies and future directions. *Cancer Control*. 2012; 19(3): 204- 13. PubMed PMID: 22710896.
- Freeman AS, Aster JC: Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. In Basow, Denise S. UpToDate. Waltham, MA: UpToDate.
- Hu Y, Yang K, Krause JR. Diffuse large B-cell lymphoma, differential, diagnosis and molecular stratification. *N Am J Med Sci*. 2011; 4(2): 67-7. doi: 10.7156/v4i2p067.
- Gatter K, Pezzella. Diffuse large B-cell lymphoma. *Diagn Histopathol*. 2010; 16(2): 69-8. doi: 10.1016/j.mpdhp.2009.12.002.
- Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. *Cancer*. 2012; 118(17):4173-83. doi: 10.1002/encr.27396. PubMed PMID: 22213394.
- Sharma S, Juffer AH. An atomistic model for assembly of transmembrane domain of T cell receptor complex. *J Am Chem Soc*. 2013; 135(6): 2188-97. doi: 10.1021/ja308413e. PubMed PMID: 23320396.
- Kingma DW, Imus P, Xie XY, Jasper G, Sorbara L, Stewart C, et al. CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms. *Cytometry*. 2002; 50(5):243-8. doi: 10.1002/cyto.10131. PubMed PMID: 12360573.
- Clark MC, Pang M, Hsu DK, Liu FT, de Vos S, Gascoyne RD, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. *Blood*. 2012; 120(23): 4635-44. doi: 10.1182/blood-2012-06-438234. PubMed PMID: 23065155. PubMed Central PMCID: PMC3512238.

16. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. *Immunol Cell Biol.* 1997; 75(5):430-45. doi: 10.1038/icb.1997.68. PubMed PMID: 9429890.
17. Richard H. "Chapter 7: B lymphocyte development and biology". In William P, editor: *Fundamental Immunology*. Philadelphia; Lippincott Williams & Wilkins; 2009. P.237–269.
18. Asano H, Imai Y, Ota S, Yamamoto G, Takahashi T, Fukayama M, et al. CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. *Int J Hematol.* 2010; 92(3):550-2. doi: 10.1007/s12185-010-0675-9. PubMed PMID: 20838960.
19. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30 anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. *Blood.* 2000; 96(12): 3681-95. PubMed PMID: 11090048.
20. Sangle NA, Agarwal AM, Smock KJ, Leavitt MO, Warnke R, Bahler D, et al. Diffuse large B-cell lymphoma with aberrant expression of the T-cell antigens CD2 and CD7. *Appl Immunohistochem Mol Morphol.* 2011; 19(6):579-83. doi: 10.1097/PAI.0b013e318221c672. PubMed PMID: 21836500.
21. Toyama T, Kubuki Y, Sasaki H, Hidaka T, Okamoto M, Suzuki M, et al. [Primary splenic CD8-positive diffuse large B-cell lymphoma]. *Rinsho Ketsueki.* 2001; 42(12):1187-91. PubMed PMID: 11828722.
22. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. *Blood.* 2009; 113(16):3773-80. doi: 10.1182/blood-2008-09-177469. PubMed PMID: 19029441. PubMed Central PMCID: PMC2943836.



ORIGINAL ARTICLE

The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran

Behnaz Habibpanah¹, Zahra Tara¹, Fatemeh Malek^{1*}, Rezvan Ardeshiri², Tahmineh Salimi³, Azam Saafi⁴, Belgheis Fasih⁵, Mohammad Reza Managhchi⁶

¹Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Shahid Dastgheib Hemophilia Center, Shiraz University of Medical Sciences, Shiraz, Iran

³Comprehensive Hemophilia Care Center, Iran University of Medical Sciences, Tehran, Iran

⁴Hematology and oncology center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

⁵Aliasghar Hospital, Zahedan University of medical sciences, Zahedan, Iran

⁶Thrombosis Hemostasis Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 03.07.2016

Accepted: 24.08.2016

Keywords:

Hemophilic patients
Patients' response
Bypassing agents

*Corresponding author:

Fatemeh Malek, Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Email: fmalek7721@gmail.com

ABSTRACT

Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients' response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents.

Methods: Hemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients' preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview.

Results: 80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was 18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products.

Conclusion: Our results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential.

Please cite this article as: Habibpanah B, Tara Z, Malek F, Ardeshiri R, Salimi T, Saafi A, Fasih B, Managhchi MR. The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran. IJBC 2016; 8(3): 72-74.

Introduction

Hemophilia A and B are X-linked disorders are the result of low levels or absence of the factor VIII (FVIII) and factor IX (FIX), respectively.¹ The mainstay of treatment in both hemophilia disorders is factor replacement therapy. As a result of replacement therapy,

20 to 35% of patients affected with hemophilia A and 6% of those with hemophilia B develop inhibitory antibodies.² Bleeding events in patients with inhibitors used to be treated by bypassing hemostatic agents during the last decades.^{1,3} Currently available bypassing agents in Iran are recombinant activated factor VII (rfVIIa;

Aryogen Aryoseven) and Feiba VH (Baxter, Deerfield, IL). Clinical observation of the patients' response to bypassing agents is still a significant task for monitoring the effectiveness of bypassing agents as no standardized and accurate assay is currently available for it. It seems that past history of the patients' response and preference could be a reliable measurement for the effectiveness of the type of the treatment.^{4,5}

The cost of managing bleeding episodes in patients with inhibitors is high and the expenses associated with bypassing therapy represents a significant liability to the patients. Considering patient's drug preference can lead to promising consequences in supplying the required products for providing better care for the hemophilic patients with lesser expenditures.⁵ The focus on discrete-choice experiment (DCE) in medical research in recent years has heightened the awareness of the patient's perspective of health outcomes.⁶ According to this approach we designed a multicentric DCE study to assess the factors that may be associated with hemophilic patients' preferences towards Aryoseven or Feiba.

Study Design

The main research question of this study was to assess hemophilic patients' preferences over the two available bypassing agents (Feiba or Aryoseven) in patients who have developed inhibitors.

Hemophilic patients older than 2 years with known inhibitors from Mofid children's hospital, "hemophilia comprehensive care center", Tehran and Imam Khomeini hospital of Tehran, Shiraz, Isfahan and Zahedan, who were in need to receive bypassing agents for the treatment of bleeding episodes were eligible to participate in this study. Patients' preferences towards treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design through a phone call interview. DCE is a quantitative method for illustrating the individual preferences. It permits researchers to demonstrate how responders value the selected attributes of a program or a product by asking them to state their choice over different hypothetical alternatives (8).

It is noteworthy to mention that Aryoseven or Feiba have been prescribed in the customary manner in accordance with the terms of the marketing authorization. In order to prevent the bias in the mentioned study, assignment of the patients to a particular therapeutic strategy was made retrospectively and decision to prescribe these agents had been made at least 3 months prior to the enrollment in the study. The objective of this study was to reach the following answers in a cross-sectional survey. A) Which aspect of a medication upon patients' view was considered important and B) Are the hemophilic patients qualified to have a preference over Aryoseven or Feiba considering the objective results of their medication.

Results

80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was 18.6 years (range, 2-50) years. 47 patients (58%) preferred Feiba, 21 patients (27%) preferred Aryoseven and 12 (15%) patients disclosed no

difference over the two products. In terms of efficacy, 18 out of 47 patients (38%) who preferred Feiba described it as excellent, 21(44%) as very good, 4 (1%) mentioned as good and 1 patient as average, respectively. Data from 3 patients was not available. On the other hand, among patients who favored Aryoseven as drug of choice, 5 patients (24%) described it as excellent, 11 (52%) as very good and 5 (24%) as average. Patients who were satisfied with Aryoseven, mentioned that their bleeding episodes were controlled with more than 3 doses of Aryoseven in 54.5%; whereas in group of patients who preferred Feiba, bleeding events were controlled with 3 doses of Feiba in 46.8% of the cases, respectively.

Features of the products which were considered by the patients to favor each drug is shown in figure 1.




Figure 1: Features considered by the patients to assign the preference of bypassing agents in hemophilic patients with inhibitors.

59% of the patients had experienced total relief of their symptoms with 3 or more doses of Feiba, 10.6% with 2 doses and 25.5% with only one dose of it; on the other hand, in Aryoseven group 59% had relief with more than 3 doses, 36.4% with 2 and 4.5% with 1 dose of the drug. In patients who received Feiba, longer injection intervals (22.5%) and side effects (21.3%) were the main reason to prefer this product.

In Aryoseven group, side effects were reported in 22.7%, longer injection intervals in 13.6% and transportability of the drug in 4.5%, respectively.

Discussion

Interpreting the preferences of the patients by health professionals could be beneficial in the field of policy making and treatment planning.⁶ A DCE is a quantitative technique for explaining the individual's preferences in different fields.⁷ It allows researchers to unveil how individuals' priorities selected particular attributes of a program or a product by asking them to share their

choices over different hypothetical alternatives. These include the elicitation of views on diagnosis, treatment and supportive care.^{7,8} In a DCE point of view, respondents are asked to choose the most-preferred alternative from a set of hypothetical profiles, assuming that these are the only alternatives available.⁸

As a matter of fact, bypassing agents do not restore the normal pathway of hemostasis in hemophilia, hence the routine laboratory coagulation assays do not assess precisely the hemostatic activity of bypassing agents, and also no validated assay is available to measure their *in vivo* efficacy or predict individual's response to the treatment. As a result, the patient's preference methods could provide an alternative and clinical method for characterizing patients' needs or priorities. In a study from Iran, Golestani et. al reported similar effects in reducing joint bleeding episodes in comparison between the two bypassing agents.⁹ Additionally, there were also other features which prompted the patients to make such preferences which included the rate of occurrence of side effects and interval of injections.

In developing countries, the idea of application of DCE to elicit the questions of health policy and treatment planning is relatively recent, but appears to be of growing interest and could be used as a resolving method unless there is more objective measures to determine the efficacy of some therapeutic options.⁶

Conclusion

To the best of our knowledge this study is the very first one based on DCE method which compares hemophilic patients' preference over the two available bypassing agent product (Aryoseven versus Feiba) for treatment of their bleeding episodes due to high titers of inhibitors. Our results indicated that according to the DCE method analysis, patients preferred Feiba to Aryoseven and the most significant reason was the more efficacy.

Acknowledgement

We would like to thank Dr Peyman Eshghi, Dr Mehran Karimi, Dr Gholamreza Toogeh, Dr Majid Naderi and Dr Hamid Hoorfar for their assist in writing this manuscript.

Conflict of Interest: None declared.

References

1. Allen G, Aledort L. Therapeutic decision-making in inhibitor patients. *Am J Hematol.* 2006; 81(1):71-2. doi: 10.1002/ajh.20474. PubMed PMID: 16369965.
2. Eshghi P, Abolghasemi H, Malek F, Naderi M, Panahi Y, Habibpanah B, et al. A prospective crossover triple-blind controlled trial on the safety and efficacy of Iranian recombinant FVIII (Safacto) versus plasma derived FVIII; A pilot study. *IJBC.* 2015; 7(4): 171-4.
3. Manucci PM. Back to the future: a recent history of haemophilia treatment. *Hemophilia.* 2008; 14(Suppl 3):10-8. doi: 10.1111/j.1365-2516.2008.01708.x. PubMed PMID: 18510516.
4. Kempton CL, White GC. How we treat a hemophilia a patient with a factor VIII inhibitor. *Blood.* 2009; 113(1):11-7. doi: 10.1182/blood-2008-06-160432. PubMed PMID: 18820129.
5. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. *J Thromb Haemost.* 2012; 10(8):1478-85. doi: 10.1111/j.1538-7836.2012.04793.x. PubMed PMID: 22632160.
6. Mangham LJ, Hanson K, McPake B. How to do (or not to do). Designing a discrete choice experiment for application in a low-income country. *Health Policy Plan.* 2009; 24(2):151-8. doi: 10.1093/heapol/czn047.
7. Bridges J, Onukwugha E, Johnson FR, Hauber AB. Patient preference methods—a patient centered evaluation paradigm. *ISPOR Connections.* 2007; 13(6):4-7.
8. John FP Bridges, Ebere Onukwugha, Brett Hauber. Patient Preference Methods - A Patient Centered Evaluation Paradigm. *Ispor Connections.* December 15, 2007.
9. Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Naderi M, et al. Cost-effectiveness analysis of biogeneric recombinant activated factor VII (AryoSeven™) and activated prothrombin complex concentrates (FEIBA™) to treat hemophilia a patients with inhibitors in Iran. *Iran J Pharm Res.* 2016; 15(2): 669–77. PubMed Central PMCID: PMC5018298.



ORIGINAL ARTICLE

Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients

Mehrdad Payandeh¹, Masoud Sadeghi^{2,3*}, Edris Sadeghi^{2,3}

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

ARTICLE INFO

Article History:

Received: 20.05.2016

Accepted: 12.07.2016

Keywords:

Colorectal cancer

Survival

Mucinous adenocarcinoma

Non-mucinous adenocarcinoma

Age

*Corresponding author:

Masoud Sadeghi,
Medical Biology Research Center,
Kermanshah University of Medical
Sciences, Kermanshah, Iran
Email: Sadeghi_mbrc@yahoo.com

ABSTRACT

Background: The oncologic behavior of mucinous adenocarcinoma (MA) of colorectal differs from non-mucinous adenocarcinoma (NMA). MA is more advanced at diagnosis and has a poorer prognosis than NMA. We aimed to evaluate prognostic factors and survival rate in patients with MA compared with NMA in Western Iran.

Methods: During 2008-2015 in a retrospective study, 83 patients with CRC referred to the Oncology Clinic in Kermanshah, Iran. Binary logistic regression analysis was used for the correlation between risk variables with the type of pathology.

Results: The mean follow-up was 32 months (range, 12-72 months) and in this interval, there were 26 deaths and 3 patients were lost to follow-up and therefore, were omitted from survival analysis. There was no significant correlation between NMA and MA with sex, degree of differentiation of tumor, tumor site, tumor size, KRAS mutation and lymph node metastasis, but a significant correlation was observed with age ($P < 0.05$). Binary logistic regression analysis showed there was a significant correlation between age ($P = 0.01$, odds ratio 11.93 and 95% CI 1.61-88.46) and type of pathology. The survival rate and mean survival were 54.3% and 23 months for NMA group, versus 80.6% and 25.4 months for MA group, respectively.

Conclusion: The prevalence of NMA in CRC was more than MA. In this study, the MA patients had lower age and more risk of recurrence compared to NMA patients and unlike other studies, 5-year survival rate was significantly higher in NMA patients than that in MA patients.

Please cite this article as: Payandeh M, Sadeghi M, Sadeghi E. Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients. IJBC 2016; 8(3): 75-79.

Introduction

Colorectal cancer (CRC) is the third most common neoplastic disease worldwide and is the second leading cause of cancer death in men and women in the United States.¹ In the World Health Organization (WHO) classification, mucinous adenocarcinoma (MA) is defined as an adenocarcinoma in which >50% of the lesion is composed of pools of extracellular mucin. Tumor with <50% of the lesion composed of mucin is categorized

as having mucinous component.² MA is a histological subtype of CRC and comprises approximately 1-6% of all colorectal epithelial cancers.³ The oncological behavior of MA differs from non-mucinous adenocarcinoma (NMA).⁴ MA is more advanced at diagnosis and has a poorer prognosis than NMA.^{3,5} MA is associated with proximal location of tumor, advanced stage at diagnosis, microsatellite instability, and BRAF and KRAS mutations compared with NMA,² however, these differences are

not definitely confirmed, yet.⁶ KRAS mutations are useful markers for predicting responses to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancers (mCRC) and CRC patients with a KRAS mutation do not respond to treatment with cetuximab or panitumumab.⁷ Clinical data have proven that mutant RAS genes are negative predictive biomarkers and that patients with a KRAS/NRAS mutation do not benefit from an anti-EGFR antibody-based therapy.⁸ We aimed to evaluate prognostic factors and survival rate in patients with MA compared with NMA in Western Iran.

Materials and Methods

Patients

During 2008-2015, in a retrospective study, 83 patients with CRC referred to the Oncology Clinic in Kermanshah city, Iran. The patients were divided into two groups based on the type of pathology (51 patients in NMA group versus 32 patients in MA group). Age, sex, degree of tumor differentiation, tumor size, tumor site, lymph node metastasis, KRAS and survival rate were studied in all patients. Overall survival (OS) was defined as the length of the time from diagnosis or the start of the treatment to death due to any cause or the date of the last follow-up.

Binary logistic regression analysis was used for the correlation between risk variables with the type of pathology. The correlation between the variables was analyzed in IBM SPSS version 19 by T-test for the means and Chi-square test for other variables. The survival graph was plotted by GraphPad Prism 5. $P < 0.05$ was significant statistically.

Results

The mean duration of follow-up was 32 months (range, 12-72 months) and in this interval, there were 26 deaths and 3 patients lost their follow-up and therefore were omitted from survival analysis. All patients had stage III or IV and there was no significant difference between stage in the two groups. The mean age (range) for NMA was 60 years (28-80 year) versus 54 years (31-78 years) for MA (Table 1). There was no significant correlation between NMA and MA with sex, degree of tumor differentiation, tumor site, tumor size, KRAS mutation and lymph node metastasis, but was a significant correlation with age ($P < 0.05$). Therefore, the mean age of MA group was lower than NMA group.

Binary logistic regression analysis between the variables and pathologic subtype of CRC has been shown in Table 2. There was a significant correlation between age ($P = 0.01$, odds ratio (OR) 11.93 and 95% CI 1.61-88.46) and type of pathology.

The 5-year OS in CRC has been shown in Figure 1 based on the type of pathology (MA group vs. NMA group). The survival rate and mean survival were 54.3% and 23 months for NMA group, versus 80.6% and 25.4 months for MA group, respectively. There was a significant correlation between survival in two groups ($P < 0.05$). Therefore, survival in MA group was better than NMA group.

Discussion

CRC is the fourth most common cancer in men and the third most common in women.⁹ Out of 255 CRC


Table 1: The correlation between type of pathology and prognostic factors in colorectal cancer (n=83)

Variables	Non-mucinous adenocarcinoma N=51	Mucinous adenocarcinoma N=32	P value
Age, years			
Mean	60	54	0.039
Range	28-80	31-78	
≥60	26 (51%)	10 (31.3%)	
Sex			
Male	30 (58.8%)	21 (65.6%)	0.061
Female	21 (41.2%)	11 (34.4%)	0.351
Differentiation			
Poorly differentiated	2 (6.9%)	1 (5.9%)	0.136
Moderately differentiated	7 (24.1%)	9 (52.9%)	
Well differentiated	20 (69%)	7 (41.2%)	
Unknown	22	15	
Tumor site			
Rectum	41 (80.4%)	21 (65.6%)	0.107
Colon	10 (19.6%)	11 (34.4%)	
Tumor size, cm			
Mean	5.6	5.5	0.968
Range	1.5-12	1.5-10	
KRAS			
Wild-type	27 (52.9%)	19 (59.4%)	0.365
Mutation	24 (47.1%)	13 (40.6%)	
Lymph node metastasis			
Yes	27 (52.9%)	19 (59.4%)	0.517
No	24 (47.1%)	13 (40.6%)	

Table 2: Binary logistic regression analysis between the variables with type of pathology

Variables	P value	OR	95% CI
Age, ≥ 60 vs < 60	0.01	11.93	1.61-88.46
Sex, male vs female	0.44	0.49	0.08-2.96
Grade, well vs moderate or poorly	0.78	0.82	0.21-3.19
Tumor site, rectum vs colon	0.10	7.65	0.66-87.98
KRAS, wild-type vs mutation	0.23	3.01	0.48-18.97
Lymph node metastasis, yes vs no	0.80	0.79	0.12-5.09

A binary logistic regression model was selected using Akaike Information Criteria (AIC) in stepwise selection. Odds ratios are adjusted for all of the factors listed in the table. OR: odds ratio.

**Figure 1:** The 5-year overall survival in colorectal cancer based on type of pathology

patients, 49 (19%) patients had a histologically confirmed diagnosis of MA.¹⁰ MA comprises approximately 1 to 6% of all colorectal epithelial cancers.⁵ In our study, out of 83 patients, 51 patients (61.4%) were NMA patients. The results of more studies has shown that the prevalence of NMA in CRC is more than MA.

In one study on CRC patients, the distribution for age at diagnosis, stage and treatment of patients with MA was similar to that of NMA patients and patients with mucinous histology had fewer well or moderately-differentiated tumors than NMA patients ($P < 0.05$).¹¹ In another study, only the tumor recurrence was significantly more common in MA, whereas the TNM stage, metastatic site and pattern of metastasis were not significantly different from each other in the two groups.³ Maksimović S. and colleagues reported that MA patients compared to patients with NMA were found to have younger age, more lymph node metastases and higher frequency of advanced stage disease ($P < 0.05$).⁵ As compared with NMA, the tumor diameter of MA was significantly longer and their age was younger. Also, MA had more lymph node metastasis and less recurrence.¹² Tumor stage and histological grading were higher in MA patients ($P < 0.001$); whereas rate of lymphatic invasion was higher in NMA.¹³ In this study, MA patients had lower age compared to

NMA patients that was a statistical significant finding, but there was no other significant correlation between sex, differentiation of tumor (grade), tumor size, tumor site, lymph node metastasis and KRAS mutations and pathologic subtype of the tumor. Although, the prognostic factors in MA and NMA patients are not the same in different studies, but the majority have reported younger age for MA tumors of colorectal and also a higher risk for recurrence in this group.

Different studies in patients with colorectal cancer has shown that prognosis of MA tumors is poorer than NMA tumors.³ One study reported that no statistically significant difference was noted in 5-year survival between MA and NMA tumors of CRC.¹² Maksimović S reported that the statistics for 5-year survival had a significant difference in MA patients compared to patients with NMA pathology (39% vs. 60.3%)⁵ and in another study, 5-year overall survival was 81.4% in MA versus 87.4% in NMA ($P = 0.005$).⁴ In patients with stage III and IV (advanced stage), MA was associated with a worse survival compared with NMA.¹⁴ It was recently reported that mucinous histology indicates a poor response to oxaliplatin and/or irinotecan-based protocols and is associated with poor overall survival. In contrast to BRAF mutations, no significant difference has been

observed in clinicopathological parameters based on KRAS genotype in many studies.¹⁵ This shows the impact of KRAS/BRAF mutations on the clinicopathological features and prognosis of the CRC patients, particularly in terms of the type of KRAS mutations; at codons 12 vs. 13.⁷ KRAS mutation was not associated with a specific clinicopathological feature including age, sex, ethnicity of the patient, site of the tumor, differentiation of the tumor and mucinous status.¹⁵ In comparison to NMA patients, MA patients had worse outcome and long-term overall survival rates. MAs may have special biological behavior which is an independent prognostic factor for patients with CRC.¹³ Five-year cause-specific survival was 67% for NMA and 61% for MA ($P < 0.05$).¹¹ After a median follow-up of 45 months in another study, median OS for MA patients was 14 months compared with 23.4 months for NMA group.¹⁶ In this study, 5-year survival rate was 54.3% (median OS, 23 months) in NMA patients compared with 80.6% (median OS, 25.4 months) for MA patients ($P < 0.05$). This result was in contrast to the results in previous studies. Therefore, genetics and probably ethnicity can affect on the metabolism of the drugs, especially anti-EGFRs that in a research,⁶ has been reported that MA have distinct clinicopathological and genetic characteristics compared to NMA. Therefore, the differences in the rate of OS in the various studies are presumed to be due to genetic differences. Future studies should focus on genetics of the patients, so can exactly check the impact of these two factors on survival.

Conclusion

In this study, the prevalence of NMA in CRC was more than MA subtype. MA patients had lower age at diagnosis and had a more risk of recurrence compared to NMA patients and unlike other studies, 5-year survival rate was significantly higher in NMA patients than that in MA patients.

Conflict of Interest: None declared.

References

- Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. *Asian Pac J Cancer Prev*. 2015; 16(17):7603-6. PubMed PMID: 26625769.
- Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. *Br J Cancer*. 2013; 108(10):1978-84. doi: 10.1038/bjc.2013.232. PubMed PMID: 23652310. PubMed Central PMCID: PMC3670503.
- Jivapaisarnpong P, Boonthongtho K. Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma in the colon and rectum in Rajavithi Hospital, Thailand. *J Med Assoc Thai*. 2011; 94 Suppl 2:S41-5. PubMed PMID: 21717877.
- Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. *Medicine (Baltimore)*. 2015; 94(15):e658. doi: 10.1097/MD.0000000000000658. PubMed PMID: 25881840. PubMed Central PMCID: PMC4602499.
- Maksimović S. [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. *Med Arh*. 2007; 61(1):26-9. PubMed PMID: 17582971.
- Tanaka H, Deng G, Matsuzaki K, Kakar S, Kim GE, Miura S, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. *Int J Cancer*. 2006; 118(11):2765-71. doi: 10.1002/ijc.21701. PubMed PMID: 16381005.
- Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? *Anticancer Agents Med Chem*. 2012; 12(2):163-71. PubMed PMID: 22043994. PubMed Central PMCID: PMC3343383.
- André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. *Ann Oncol*. 2013; 24(2): 412-9. doi: 10.1093/annonc/mds465. PubMed PMID: 23041588.
- Madani SH, Sadeghi E, Rezaee A, Sadeghi M, Khazaei S, Amirifard N, et al. Survey of HER2-neu expression in colonic adenocarcinoma in the west of Iran. *Asian Pac J Cancer Prev*. 2015; 16(17):7671-4. doi: 10.7314/APJCP.2015.16.17.7671. PubMed PMID: 26625779.
- Catalano V, Loupakis F, Graziano F, Torresi U, Bissonni R, Mari D, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. *Br J Cancer*. 2009; 100(6):881-7. doi: 10.1038/sj.bjc.6604955. PubMed Central PMCID: PMC2661784.
- Xie L, Villeneuve PJ, Shaw A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. *Int J Oncol*. 2009; 34(4):1109-15. doi: 10.3892/ijo_00000238. PubMed PMID: 19287969.
- Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, et al. [Clinical features of colorectal mucinous adenocarcinoma]. *Zhonghua Wei Chang Wai Ke Za Zhi*. 2009; 12(5):487-90. PubMed PMID: 19742341.
- Nitsche U, Zimmermann A, Späth C, Müller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. *Ann Surg*. 2013; 258(5):775-82; discussion 782-3. doi: 10.1097/SLA.0b013e3182a69f7e. PubMed PMID: 23989057. PubMed Central PMCID: PMC3888475.
- Numata M, Shiozawa M, Watanabe T, Tamagawa H, Yamamoto N, Morinaga S, et al. The

- clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. *World J Surg Oncol.* 2012; 10:109. doi: 10.1186/1477-7819-10-109. PubMed PMID: 22703761. PubMed Central PMCID: PMC3407705.
15. Phua LC, Ng HW, Yeo AH, Chen E, Lo MS, Cheah PY, et al. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. *Oncol Lett.* 2015; 10(4):2519-26. doi: 10.3892/ol.2015.3560. PubMed PMID: 26622882. PubMed Central PMCID: PMC4579971.
 16. Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. *Ann Oncol.* 2005; 16(8):1305-10. doi: 10.1093/annonc/mdi244. PubMed PMID: 15857840.



ORIGINAL ARTICLE

Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients

Ali Ghasemi¹, Sadegh Abbasian^{1*}, Kazem Ghaffari², Zeynal Salmanpour³

¹Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

²Department of Hematology, School of Allied Medical Sciences, Arak University of Medical Sciences, Arak, Iran

³Department of Hematology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 02.05.2016

Accepted: 23.07.2016

Keywords:

Alloimmunization
Autoimmunization
Thalassemia
Transfusion

*Corresponding author:

Sadegh Abbasian,
Blood Transfusion Research Center,
High Institute for Research and
Education in Transfusion Medicine,
Tehran, Iran
Email: sadegh_abasian@yahoo.com

ABSTRACT

Background: The development of anti-red blood cell alloantibodies remains a major problem in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in clinical hemolysis and difficulty in cross-matching blood. We studied the frequency of red blood cell alloimmunization and autoimmunization among thalassemia patients who received regular transfusions in Ilam province of Iran.

Methods: This study was carried out on 110 multiply transfused patients with thalassemia major. The saline method, Albumin method, direct/indirect coombs' and Three cell panel test used for detection of red blood cell alloantibody/autoantibody.

Results: 12 patients out of total 110 patients (10.9 %) developed alloantibodies and 2 (1.81 %) developed autoantibodies. Rh and Kell blood group system alloantibodies were most commonly found, with the majority of patients being transfused with blood matched for ABO and D antigens only.

Conclusion: This study suggests screening RBC antigens prior to transfusion. Our findings accentuate the necessity of antigen typing of supposed to be transfused red blood cells and screenings tests before the first transfusion, at least for Rh (Rh system) and Kell (Kell system) antigens.

Please cite this article as: Ghasemi A, Abbasian S, Ghaffari K, Salmanpour Z. Prevalence of Alloantibodies and Autoantibodies in Transfusion Dependent Thalassemia Patients. IJBC 2016; 8(3): 80-85.

Introduction

Red blood cell (RBC) alloimmunization is an immune response against foreign RBC antigens; this generally occurs after sensitization due to blood transfusions and pregnancies.¹ Rh, Kell, Kidd and Duffy alloantibodies have a high clinical importance; they react at 37°C and cause hemolysis in transfused patients, fetuses and newborns.¹⁻³ Thalassemia is the most common genetic disorder worldwide and is the most common hereditary hemolytic anemia have been considered.^{4,5} The disease has a high prevalence in the Mediterranean in the Middle East (Iran), India, and Southeast Asia is seen.^{6,7} There are many forms of thalassemia due to decreased synthesis or lack of synthesis occurs in one or more chains of hemoglobin

molecules.^{8,9} The expansion of anti-RBC alloantibodies and autoantibodies can significantly make difficulties transfusion therapy. Various alloantibodies are hemolytic and may cause, however not regularly, hemolytic transfusion reactions and limit the availability of further safe transfusion. Others are clinically insignificant. Erythrocyte autoantibodies appear fewer commonly, but they can result in clinical hemolysis and in difficulty in cross-matching blood. Patients with autoantibodies may have a higher transfusion proportion and often require immunosuppressive drugs, a splenectomy, or alternative managements. Life-long RBC transfusion remnants the chief treatment for major thalassemia.¹⁰⁻¹² In spite of the recognition of autoantibodies as transfusion-related

threats, little is known about the extent and reasons of these occurrences among thalassemia patients or the suitable inhibition procedures. Methods for inhibition or management of alloimmunization are under discussion. They vary from providing of RBCs matched for all the major antigens associated with clinically significant antibodies to blood matched only for antibodies that have already been made. Aims for controversy as to the best approach lay in the fact that numerous alloantibodies are not harmful, and costly inhibition procedures may therefore benefit only some patients.¹³⁻¹⁵ Conventional therapy is transfusion life-long regular blood which reduces the severe complications of anemia, maintain growth and increase the survival.^{8,9,16,17} However, transfusion will seek out the complications includes iron overload, infections and alloantigens and autoantibodies formed against antigens from red blood cells.^{5,6,17} Repeated blood transfusion in these patients, different antigens on red blood cells enter into the patient's body and stimulate the patient's immune system to produce alloantibodies and autoantibodies. Since when choosing a transfusion blood just ABO and RH groups controlled, most alloantibodies formed against other blood group systems which cause delayed hemolytic reactions and limits further safe transfusion and cross-matching is also faced with the problem. Some alloantibodies also are clinically insignificant.^{5,9,18} Knowing the side effects of blood transfusion, is a major problem in the treatment of patients with thalassemia. The purpose of this study was to determine the prevalence of alloimmunization and erythrocyte autoimmunization among thalassemia patients who received regular transfusions in Ilam province of Iran.

Materials and Methods

After obtaining consent from all patients, clinical and transfusion informations of 110 transfusion dependent thalassemia patients (range: 10-35 years) who received regular transfusions were studied. The transfusion informations of all patients were studied for the presence of alloimmunization or autoimmunization, and antibody specificity. 110 patients who initially had negative results for RBC Alloantibodies/autoantibodies, were enrolled in the study. All patients were questioned and filled a questionnaire comprising of kind of thalassemia, date of the first blood transfusion, transfusion blood type (standard, washed, leucoreduced), hematocrite/hemoglobin level, reticulocyte count, direct and indirect Coombs test, total and direct bilirubin, hemoglobinuria and the type of alloantibody, as well as signs and symptoms like infection, dyspnea, chill, jaundice and pain (Table 1).

Sample from patients who received regular transfusions was drained in tubes containing acid citrate dextrose 21 days after the patients received a packed RBC transfusion and just before their next transfusion. Blood group typing done by Anti-A, Anti-B anti-D reagent (Iranian Blood Research and Fractionation Holding Company, Tehran-Iran) in Tube test procedure for each patient. Prior to each transfusion for detection of new Alloantibodies/

Table 1: Post-transfusion clinical and laboratory investigations in thalassemia patients with alloimmunization.

Post transfusion assessments	Percent
Positive direct coombs test	82
Increased reticulocyte count	58
Hemoglobinuria	52
Headache	63
Backache	66
Jaundice	63
Chill	62
Infection	42
Dyspnea	41

autoantibodies to RBC antigens, serum was analyzed by means of standard blood bank procedures. The serum was mixed with saline-suspended red cells with the addition of low ionic strength saline (LISS) and incubated at 37°C for 15 minutes. Alloantibody screening and identification was done using 3-cell antigen panel in Ilam blood transfusion organization (Iran blood transfusion organization, Iran, Lot No: 119405), and an anti-IgG reagent was used for the antiglobulin phase (synagen, Lot No: m4051). The panel test which determines 18 blood groups for the following antigens "D, C, E, e, c, K, k, M, N, S, s, Fy^a, Fy^b, Jk^a, Jk^b, Le^a, Le^b and P". Briefly, four drops of patient's serum add to be tested to each labeled tube. Then, two drop of thoroughly mixed reagent RBC add to the appropriate labeled tube. Subsequently, two drops of Albumin 22% added to each tube (Refining and blood research, Lot No: 89.BSA05). After mixing the contents of each tube, incubate all tubes at room temperature and 37°C (±1°C) for 15-30 minutes. Then proceed directly with the antiglobulin test phase following incubation. Wash tubes a minimum of 3 times with isotonic saline. Completely decant saline after final wash to obtain a "dry" red cell button. Add two drops anti-IgG to each tube. Centrifuge tubes in 3000 RPM for 1-3 minute. Immediately re-suspend the cells by gentle agitation; examine the tubes macroscopically for agglutination. If the screen was positive, an extended panel to recognize the antibody and a direct antiglobin (DAT) was implemented. Absorption techniques were employed in patients presenting with a new autoantibody. In cases of a positive DAT, additional study using specific reagents to detect IgG, IgM, or a complement were approved according to manufactory method in room temperature and 37C. When an antibody was detected, eluates were prepared and confirmed against common sample RBCs. polyethylene glycol was used to enhance the reactivity.

Results

There were 48 (43.7%) females and 62 (56.3) males. The mean age of patients was 22.5 (1SD±9.5). The mean age for the first blood transfusion was 5 (1SD±3.6) months for thalassemia major. 12 patients out of total 110 patients (10.9%) developed alloantibodies and two (1.81%) developed autoantibodies. The identified alloantibodies contains: D, C, E, c, K, Jk^a, Fy^a and Le^a (Table 2).

Table 2: Prevalence of alloantibodies in patients

Blood Groups	Number (%)
RH system	7 (58.3)
D	4 (33.4)
C	1 (8.3)
E	1 (8.3)
c	1 (8.3)
Kell system	2 (16.6)
Kidd system	1 (8.3)
Duffy system	1 (8.3)
Lewis system	1 (8.3)

Anti-D and anti-Le^a, was the most prevalent clinical significant, and non-significant antibodies, respectively. There was not any significant relationship between sex and prevalence of alloantibody ($p > 0.05$). There was not any significant relationship between age and prevalence of alloantibody ($p > 0.05$) (Table 3).

Prevalence of alloantibody in this study was 10.9% (12 patients) and 89.1% (98 patients) showed no alloantibody in their serum. Of 12 alloimmunized patients, 7 patients (11.3% of male patients) were male and 5 patients (10.4% of female patients) were female. The identified autoantibodies contains: P and N. Anti-P and anti-N were not clinical significant. Results of this study indicate low frequency of RBCs alloimmunization. The incidence of alloimmunization according to blood group was not confirmed. The alloantibody of 4 patients (33.33%) was recognized within six days of the transfusion; of 3 (25%) within ten days; of 2 (16.66%) within Thirty days; of 2 (16.66%) within 35 days and 1 (8.3%) within three months. The autoantibody of 1 patient (50%) was recognized within two months of the transfusion and 1 (50%) within four months. The highest titer was 1:128 (for anti-D) and lowest titer was 1:8 (for anti-Jk^a). There was no significant correlation between alloimmunization rate and patients who regularly used washed/leukoreduced packed cell.

Table 3: Correlation between sex and age with prevalence of alloantibody

Characteristics	Total	Non-alloimmunized		Alloimmunized		OR (95% CI)	P value
		n	(%)	n	(%)		
Number of Patients, (%)	110	98	(89.1)	12	10.9)	-	-
Age 8-19 years	73	66	(90.41)	7	9.58)	0.909 (0.309-2.495)	0.999
≥20 years	37	32	(86.48)	5	(13.51)		
Sex						0.925 (0.318-2.582)	0.999
Male	62	55	(88.7)	7	11.3)		
Female	48	43	(89.6)	5	(10.4)		

Fisher's Exact Test; OR: Odds Ratio

Table 4: Correlation between sex and age with prevalence of autoantibody

Characteristics	Total	Non-autoimmunized		Autoimmunized		OR (95% CI)	P value
		n	(%)	n	(%)		
Number of Patients, (%)	110	108	(98.18)	2	(1.81)	-	-
Age 8-19 years	73	73	(100)	0	-	0.800 (0.056-11.512)	
≥20 years	37	35	(94.6)	2	(5.40)		1.000
Sex						0.800 (0.056-11.512)	1.000
Male	62	62	(100)	0	-		
Female	48	6	(95.9)	2	(4.1)		

Fisher's Exact Test; OR: Odds Ratio

Out of 12 patients with alloantibodies 10 patients were found with two antibody, and 2 had three antibodies. The antibody screening panel test was positive in 39 patients (35.45%). There was not any significant relationship between sex and prevalence of autoantibody ($P > 0.05$). There was not any significant relationship between age and prevalence of autoantibody ($P > 0.05$) (Table 4). For patients who were on iron chelator (desferrioxamine), the pre-transfusion hemoglobin level was less than 8 gm/dl and post-transfusion hemoglobin level was 13 gm/dl. Patients who were not on iron chelator, the pre transfusion hemoglobin level was less than 8 gm/dl and post transfusion hemoglobin level was 11 gm/dl.

Patients with O negative blood group were the most frequent alloimmunized subjects, while patients with B negative and AB negative blood groups had the lowest frequent of alloimmunized subjects. Nevertheless, no significant risk or safety was well-known by the OR/p-value; the existence of alloimmunization in relation to blood group was not confirmed (Table 5).

Discussion

In our study, prevalence of alloantibody was 10.9%. The most prevalent antibody was against D antigen. Transfusion of red blood cells (RBCs) is a public method in the management of patients with major thalassemia for two reasons: (1) transfusion of packed cells increases the oxygen-carrying capacity of the blood in the patients with major thalassemia, and (2) the replacement of the non-functional RBCs with functional ones may improve the symptoms or avoid the complications of the disorder. Alloimmunization against blood groups occurs following transfusion, pregnancy and transplantation. In patients who are transfused regularly such as thalassemia and sickle cell anemia patients the frequency of alloimmunization is high.¹⁹ The rate of alloimmunization in the other parts of Iran has been reported as following: 7.4% (Tehran),

Table 5: Incidence of post-transfusion alloimmunization in patients with major thalassemia in relation to the ABO/RhD blood group

Blood group	Total	Non-alloimmunized		Alloimmunized		OR (95% CI)	P value	
		n	(%)	n	(%)			Antibodies
O positive	42	37	88	5	12	Anti-C Anti-K Anti-Lea Anti-Fya	0.701 (0.102-4.989)	0.826
O negative	13	9	70	4	30	Anti-D (x 3) Anti-K	0.356 (0.051-2.098)	0.124
A positive	16	15	94	1	6	Anti-c	0.413 (0.401-1.950)	0.928
A negative	7	6	86	1	14.3	Anti-D	0.572 (0.015-11.201)	0.999
B positive	19	17	89.5	2	10.5	Anti-K Anti-E	0.345 (0.078-8.107)	0.819
B negative	4	4	100	0	0	-	0.417 (0.008-3.207)	0.999
AB positive	7	6	86	1	14.3	Anti-JKa	0.978 (0.008-0.189)	0.0504
AB negative	2	2	100	0	0	-	0.347 (0.123-1.206)	0.0321

Fisher's Exact Test; OR: Odds Ratio

5.34% (Fars province), 18.7% (Southwest Iran) and 2.87% (Northeast Iran).^{7,19} Furthermore, the alloimmunization frequency in other countries is 30% (Kuwait), 19.5% (Egypt), 7.4% (Hong Kong), 5% (Italy), 8% (India), and 3.7% (Greece).^{7,18,20-22} Compared with Kuwait and Egypt, Results of this study point out low incidence of RBCs alloimmunization. This low alloimmunization frequency indicates that there is homogeneity of red cell antigens in blood donors & recipients. The antibody screening panel test was positive in 45 patients (40.9%). In another study in Southwest Iran (Ahvaz), the antibody screening panel test was positive in 42 patients (32.06%).¹⁹ Also, two patients (4.1%) had autoantibody, while in another study in Southwest Iran (Ahvaz) was 12.7%.¹⁹ Keikhaei, B., et al. Showed that the predominant pattern of alloimmunization was alloantibodies against RH sub-groups system in 55 percent of patients and 33% of patients had alloantibodies against Kell system.¹⁹ In this study, we demonstrated that the predominant pattern of alloimmunization was alloantibodies against RH system (D, C, E and c) in 58.3 percent of patients and 16.6 percent of patients had alloantibodies against Kell system. One cause for the high incidence of anti-D among patients may mostly be due to lack of enough knowledge and education about weak D, partial D and Del• phenotypes in blood bank staff. So it is necessary for blood bank professionals and other healthcare employees involved in blood transfusion, to be well informed about these phenotypes. The D antigen is composed of numerous epitopes (designated by “epD”). Subsequent studies with monoclonal antibodies defined 30 or more epitopes designated as “epD1” to “epD9”.²³ Amino acid changes in intracellular regions of the protein may alter D epitopes. Altered D is organized into four groups: weak D, partial D (including category D), Del• and nonfunctional RHD.²⁴⁻²⁷ One of the most important reasons for alloimmunization is the transfusion of some red blood cells with rhesus D incompatible with thalassemia patients due to false negative results in D typing of blood donors. Traditionally, weak D red cells were defined as having a reduced amount of D antigen (formerly called “D^w”) that required an indirect antiglobulin test (IAT) for detection. Weak D types are the result of an SNP

that encodes a single amino acid change predicted to be located in the intracellular or transmembrane region of the protein, rather than on the outer surface of the red cell. The amino acid changes may affect the insertion of the protein in the membrane and, thus, reflect the reduced number of D antigen sites on the red cells.²⁵ A weak D phenotype can occur with many partial D phenotypes, Ce in trans with suppression of RHD, in the Rh_{mod} phenotype, and via autosomal recessive inheritance of two weak RHD alleles. The latter accounts for the majority of weak D phenotypes present in the general population. Because all the mutations are intramembranous or intracellular, it is assumed they do not significantly alter the presentation of D epitopes on the extracellular loops. This may explain why most weak D individuals do not make alloanti-D when transfused with D positive blood.^{25,28} Partial D antigens are RHD proteins with missing D epitopes. Although they type as D-positive, persons with partial D antigens can make alloanti-D antibodies reactive with allogeneic, but not autologous, RBCs. The alloanti-D produced by these individuals recognizes D-specific epitopes missing on their own RBCs. In contrast to weak D types, partial changes are predicted to be located on the exterior membrane surface. Some partial D types are detected only by the IAT. Red cells that express extremely low levels of D antigen that cannot be detected by routine serologic methods are designated as “D-elution” or D_{el}. Del cells are found in 10% to 30% of D-negative people of Asian ancestry. It is worth noting that the identification of weak D phenotype in blood recipients is not necessary because they do not develop anti-D, after receiving D-positive blood. But partial D phenotypes need to be identified because transfusion of D-positive blood to partial D subjects will lead to alloimmunization. Hence, it is recommended to consider a separate refrigerator for storing products supposed to be given to patients with major thalassemia. We also recommend to do following experiments on the blood that is supposed to be transfused to patients with major thalassemia:

1- Using anti-D reagents combine a monoclonal IgM, which causes direct agglutination at room temperature, with a monoclonal or polyclonal IgG that is reactive by

IAT for the determination of weak D.

2- Typing Donors for D: The aim of D typing of RBC donors, including the identification of units with weak D or partial D types, is to prevent anti-D immunization of recipients. A unit labeled Rh negative must be confirmed by testing an integrally attached segment before transfusion. Weak D testing is not required. The RhD type of the units labeled Rh positive do not require confirmatory testing.

3- Typing Patients for D: When the D type of a patient is determined, a weak D test is not essential except to assess the red cells of an infant whose mother is at risk of D immunization. Monoclonal IgM reagents type numerous samples as being D positive in direct testing that would have previously been identified only by IAT. Consequently, some of the concerns regarding the unnecessary use of Rh-negative blood and RhIG have been addressed.

4- D typing discrepancies should always be inspected and resolved. An Rh-negative blood transfusion is an appropriate option for patients needing immediate transfusion, but a thorough clerical and serologic investigation should be performed. *RHD* genotyping is also useful to resolve D typing discrepancies. Because donor centers test for weak D, a donor who is correctly classified as Rh positive may be classified as Rh negative as a recipient. This discrepancy should not be considered problematic but, rather, should be communicated to the patient and health-care staff and be noted in the patient's medical record.

5- Inappropriately, serologic reagents cannot certainly be used to differentiate persons with partial D that is reactive only with improved techniques and procedures from D-positive persons. Many partial D red cells type as strongly D positive in direct tests and are known only after the patients produce anti-D. Guidelines regarding D typing techniques and choice of blood components for transfusion should be based on the patient population, risk of immunization to D, and limited supply of D-negative blood components. These guidelines should state what should be done when a partial D type is found before the patient makes anti-D. Anti-D is a clinically significant antibody, and preventing immunization in females of childbearing potential is important to avoid the complications of HDFN.

6- RH genotyping: RH genotyping is an effective attachment to serologic testing for the typing of transfused patients, RHD zygosity determination, noninvasive fetal D typing, determination of D status, and identification of antigen-matched blood for patients with major thalassemia.

7- Typing multi-transfused patients: In patients receiving chronic or massive transfusions, the existence of donor red cells in the peripheral blood often makes red cell phenotyping by agglutination incorrect or problematic. Genotyping overcomes this restriction because blood grouping can be determined with DNA prepared from a blood sample, though the sample was collected after transfusion.

8- D-negative, first-time donors are screened for RHD

to detect red cells with very weak D.

By several factors, alloimmunization is limited in the traditional practice of transfusion of blood. Many of the antigens present on RBCs uncommonly give rise to alloimmunization even when injected into patients lacking the antigen.²⁹ The factors for alloimmunization are complex and involve at least 3 main contributing features: The RBC antigenic difference between the blood donor and the recipient; the recipient's immune status; and the immunomodulatory effect of the allogeneic blood transfusions on the recipient's immune system. A low rate of alloimmunization may be expected when there is homogeneity of RBC antigens between the blood suppliers and recipients.¹⁸ The ability to respond to alloantigens differs importantly from person to person. Some individuals will not become immunized to any antigens in spite of continuous transfusion, whereas others will become immunized, when transfused, to many of the antigens that they lack.³⁰ Blood banks will provide enough compatible blood for patients with thalassemia. Ameen et al. have reported Anti-K in 72% of patients and anti-E in 45.6%³¹ and in our study Anti K, anti-E, anti-C, anti-c and anti D were found in 16.6%, 8.3%, 8.3%, 8.3% and 33.4 of patients respectively. In another study, Karimi et al. detected high prevalence of antibodies against Rh system (47.7%).³² In Europe and the United States, the most commonly reported alloantibody in alloimmunized patients were alloantibody against Rh and Kell antigens. In a study in Minnesota, also anti-E and anti-K had higher rate than the other.³³ RBCs alloantibody formation was not influenced by gender, age at start of transfusions and number of packed cells received.

Conclusion

This study suggests screening RBC antigens prior to transfusion. Our findings accentuate the necessity of antigen typing of supposed to be transfused red blood cells and screenings tests before the first transfusion, at least for Rh (Rh system) and Kell (Kell system) antigens.

Conflict of Interest: None declared.

References

1. Novaretti M. Investigaç o laboratorial em pacientes com anticorpos eritrocit rios. Bordin JO, Langhi J nior DM, Covas DT Hemoterapia: fundamentos e pr tica S o Paulo: Atheneu 2007:186-189.
2. Baptista-Gonz lez H, Rosenfeld-Mann F, P rez-P rez J, et al. Anticuerpos irregulares antieritrocitarios fuera del sistema ABO en el periodo perinatal. Bolet n M dico del Hospital Infantil de M xico 1991;48:814-819.
3. Lee C, Ma E, Tang M, et al. Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy—a review of cases from 1997 to 2001. Transfusion Medicine 2003;13:227-231.
4. Safari Moradabadi A, Alavi A, Eqbal Eftekhaari T. The reproductive behavior of families with Thalassaemic children in Hormozgan. Journal of

- Reproduction & Infertility 2015;16:167-170.
5. Azarkeivan A, Ansari S, Ahmadi MH, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. *Pediatric hematology and oncology* 2011;28:479-485.
 6. Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). *Transfusion* 2014;54:972-981.
 7. Sadeghian MH, Keramati MR, Badiie Z, et al. Alloimmunization among transfusion-dependent thalassemia patients. *Asian journal of transfusion science* 2009;3:95.
 8. Ahmed AM, Hasan NS, Ragab SH, et al. Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients. *Arch Med Sci* 2010;6:592-598.
 9. Chao Y-H, Wu K-H, Lu J-J, et al. Red blood cell alloimmunisation among Chinese patients with β -thalassaemia major in Taiwan. *Blood Transfusion* 2013;11:71.
 10. Kruatrachue M, Sirisinha S, Pacharee P, et al. An association between thalassaemia and autoimmune haemolytic anaemia (AIHA). *Scandinavian journal of haematology* 1981;25:259-263.
 11. Argioli F, Diana G, Arnone M, et al. High-dose intravenous immunoglobulin in the management of autoimmune hemolytic anemia complicating thalassemia major. *Acta haematologica* 1990;83:65-68.
 12. Cianciulli P, Sorrentino F, Morino L, et al. Radiotherapy combined with erythropoietin for the treatment of extramedullary hematopoiesis in an alloimmunized patient with thalassemia intermedia. *Annals of hematology* 1996;72:379-381.
 13. Ness PM, Shirey R, Thoman S, et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. *Transfusion* 1990;30:688-693.
 14. Ness PM. To match or not to match: the question for chronically transfused patients with sickle cell anemia. *Transfusion* 1994;34:558-560.
 15. Fluit C, Kunst V, Drenthe-Schonk A. Incidence of red cell antibodies after multiple blood transfusion. *Transfusion* 1990;30:532-535.
 16. Glaser A, McColl B, Vadolas J. The therapeutic potential of genome editing for β -thalassemia. *F1000Research* 2015;4.
 17. Ragab LA, Hamdy MM, Shaheen IA, et al. Blood transfusion among thalassemia patients: A single Egyptian center experience. *Asian journal of transfusion science* 2013;7:33.
 18. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood* 2000;96:3369-3373.
 19. Keikhaei B, Hirad Far A, Abolghasemi H, et al. Red Blood Cell Alloimmunization in Patients with Thalassemia Major and Intermediate in Southwest Iran. *Iranian Journal of Blood and Cancer* 2013;6:41-46.
 20. El Danasoury AS, Eissa DG, Abdo RM, et al. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. *Transfusion* 2012;52:43-47.
 21. Ho H-K, Ha S-Y, Lam C-K, et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. *Blood* 2001;97:3999-4000.
 22. Patel AS, Gamit S, Gohil M. Role of RBC's alloimmunization in multiple transfused thalassaemia patients. *International Journal of Research in Medical Sciences* 2016;4:822-828.
 23. Scott M, Voak D, Liu W, et al. Epitopes on Rh proteins. *Vox sanguinis* 1999;78:117-120.
 24. Ye L, Wang P, Gao H, et al. Partial D phenotypes and genotypes in the Chinese population. *Transfusion* 2012;52:241-246.
 25. Wagner FF, Gassner C, Müller TH, et al. Molecular basis of weak D phenotypes. *Blood* 1999;93:385-393.
 26. Shao CP, Maas JH, Su YQ, et al. Molecular background of Rh D-positive, D-negative, Del and weak D phenotypes in Chinese. *Vox sanguinis* 2002;83:156-161.
 27. Sun C-F, Chou C-S, Lai N-C, et al. RHD gene polymorphisms among RhD-negative Chinese in Taiwan. *Vox sanguinis* 1998;75:52-57.
 28. Pham BN, Roussel M, Peyrard T, et al. Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies? *Transfusion* 2011;51:2679-2685.
 29. Giblett ER. A Critique of the Theoretical Hazard of Inter vs. Intra-Racial Transfusion*. *Transfusion* 1961;1:233-238.
 30. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. *Blood* 1990;76:1431-1437.
 31. Ameen R, Al-Shemmari S, Al-Humood S, et al. RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. *Transfusion* 2003;43:1604-1610.
 32. Karimi M, Nikrooz P, Kashef S, et al. RBC alloimmunization in blood transfusion-dependent β -thalassemia patients in southern Iran. *International journal of laboratory hematology* 2007;29:321-326.
 33. Reyhaneh K, Ahmad G, Gharib K, et al. Frequency & specificity of RBC alloantibodies in patients due for surgery in Iran. *The Indian journal of medical research* 2013;138:252.



CASE REPORT

Lineage Switch in Childhood Leukemia: A Case Report and Review of Literature

Shiva Nazari¹, Fatemeh Malek^{2*}, Navid Zavvar¹

¹Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 01.05.2016

Accepted: 18.07.2016

Keywords:

Leukemia
Children
Cell lineage

*Corresponding author:

Fatemeh Malek, MD
Pediatric Respiratory Diseases
Research Center, National Research
Institute of Tuberculosis and Lung
Diseases (NRITLD), Shahid Beheshti
University of Medical Sciences,
Tehran, Iran
Email: fmalek7721@gmail.com

ABSTRACT

Acute leukemia which is the most common cancer in children is a heterogeneous group of clonal malignancies. The conversion of the leukemic cell lineage during the course of the disease or later is termed lineage switch. It has been rarely reported in the literature. In leukemia lineage switch, conversions from lymphoblastic leukemia to myeloid leukemia or vice versa are reported. Herein, we report a 7-year-old child with acute lymphoblastic leukemia which switched to acute myeloid leukemia upon relapse.

Please cite this article as: Nazari S, Malek F, Zavvar N. Lineage Switch in Childhood Leukemia: A Case Report and Review of Literature. IJBC 2016; 8(3): 86-87.

Introduction

Acute leukaemia is a heterogeneous group of clonal malignancies categorized as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or mixed phenotype acute leukemia (MPAL). All subtypes have cytogenetic and molecular alterations that have prognostic implications. Lineage switch which is the conversion of the leukemic clone is known to be associated with poor prognosis.¹⁻³ There are occasional reports of switch in leukemic cell lineage (lymphoid or myeloid) through the course of the disease in the literature.¹⁻³ Distinct hypotheses have been considered to explain the lineage switch.³ Here, we present the clinical and laboratory features of a case with pre B ALL who switched to AML as a relapse.

Case Presentation

A 7-year-old boy was admitted to Mofid Children's Hospital with a history of pallor, abdominal pain, chemosis and cervical lymphadenopathy. The initial laboratory findings demonstrated a white blood cell count of $5.3 \times 10^9/L$, 56% Neutrophils, 44% lymphocytes, Hemoglobin 8 g/dL, and platelet $149 \times 10^9/L$. Bone marrow aspiration was cellular with 94% blasts which were medium-sized. Immunophenotyping was as follows: HLA-DR (71.5%), CD10 (10%), CD19 (90%), CD20 (95%), CD22 (43%), CD13 (2%) and CD33 (8%) which was in favor of B lineage acute leukemia.

Cytogenetic study was positive for t(8,14) and karyotype demonstrated 46 XY with duplication of one segment of long arm of chromosome 1. The patient was treated

with protocol for B-Cell ALL (LMB 89 Protocol). Chemotherapy was continued for three years and the patient was in complete remission. At that time, the patient developed a short period of pancytopenia whom underwent bone marrow aspiration for further evaluation. It revealed complete infiltration of blasts which according to flowcytometry was compatible with AML. Immunophenotyping was positive for CD13 (63%), CD33 (34%), CD15 (43%), HLA-DR (82%), CD117(66%), CD45(89%),c MPO(57%), CD22 (43%), CD10 (1%), CD19 (1%), CD20 (1%) which accordingly diagnosis of AML non-M3 was established. Karyotype was unsuccessful at this time. The patient received AML directed chemotherapy and also was scheduled to go through allogeneic stem cell transplantation; however, remission was not achieved and the patient died of the disease.

Discussion

Although rarely, switches between lymphoid and myeloid lineages may occur during treatment of acute leukemias.⁴ Among suggested hypotheses for lineage switch is a deviation in the initial leukemic clone which actually had been MPAL; hence, the first diagnosed lineage would be converted to another at a later time.⁴⁻⁶ In other words, lineage switch could be a part of the biologic spectrum of mixed-lineage leukemias.⁴⁻⁷ Rossi and colleagues proposed the involvement of early bipotential B-macrophage progenitors in the course of lineage switch raising the possibility that the lineage switching event would be the conclusion of the leukemogenic mutations targeting this early bi-potential progenitor cell.⁴⁻⁸ Additionally another explanation by Strass and co-workers could be the selection of a pre-existing chemotherapy-insensitive minor population of cells of different lineage among the predominant population of leukemic blasts at diagnosis; (biphenotypic or bilineage leukemias) resulting in a resistant subclone with expression of different antigens.^{4,5,9}

In our patient, immunophenotyping showed a new myeloid population. The emergence of chemo-resistant subclones that are undetectable by regular methods or substitution of a new leukemic clone are probably possible and neither of them could be ruled out for our patient. Cytotoxic drugs are responsible for the process of phenotypic conversion by inducing a multipotential clone or as a cause of inducing drug-resistant clones in case of multiclonal leukemia.⁷ In a study from Argentina published in 2012, frequency of lineage switch in childhood leukemia was 0.6% (9 patients), which was from lymphoid to myeloid in 7 and from myeloid to lymphoid in 2 cases.⁴ Although, the principle mechanisms involved in lineage switch continue to be unclear, plasticity of leukemic progenitors which could be multidirectional and reversible is suggested as a possible hypothesis.¹⁰

Conclusion

We described a case of lineage switch leukemia from ALL to AML which is a rare event. Correct diagnosis

relies upon confirmation by immunophenotyping of the lineage conversion and certification that the same cytogenetic/molecular alterations remain despite the phenotypic changes. Prognosis of lineage switch leukemia is poor as our patient could not achieve a remission and dies of his disease.

Conflict of Interest: None declared.

References

1. Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. *Nat Commun.* 2016; 7:12320. doi: 10.1038/ncomms12320.
2. Dorantes-Acosta E, Arreguin-Gonzalez F, Rodriguez-Osorio CA, Sadowinski S, Pelayo R, Medina-Sanson A. Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report. *Cases J.* 2009; 2:154. doi: 10.1186/1757-1626-2-154. PubMed PMID: 19946525. PubMed Central PMCID: PMC2783110.
3. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, et al. Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse. *Int J Clin Oncol.* 2010; 15(1):112-5. doi: 10.1007/s10147-009-0007-3. PubMed PMID: 20066454.
4. Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, et al. Lineage switch in childhood acute leukemia: An unusual event with poor outcome. *Am J Hematol.* 2012; 87(9):890-7. doi: 10.1002/ajh.23266. PubMed PMID: 22685031.
5. Stass SA, Mirro J Jr. Lineage heterogeneity in acute leukaemia: acute mixed-lineage leukaemia and lineage switch. *Clin Haematol.* 1986;15:811-27. doi: 10.1016/S0046-8177(85)80125-8. PubMed PMID: 3536242.
6. Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. *Blood.* 1984; 64(3): 701-6. PubMed PMID: 6590097.
7. Mura R, D'angelo P, Rizzari C, Biondi A, Giudici G, Crosti L, et al. Lineage switch in a childhood T-Cell acute lymphoblastic leukemia. *Pediatr Hematol Oncol.* 1992; 9(3):281-8. doi: 10.3109/08880019209016598.
8. Park M, Koh KN, Kim BE, Im HJ, Jang S, Park CJ, et al. Lineage switch at relapse of childhood acute leukemia: a report of four cases. *J Korean Med Sci.* 2011; 26(6): 829-31. doi: 10.3346/jkms.2011.26.6.829. PubMed Central PMCID: PMC3102880.
9. Gagnon GA, Childs CC, LeMaistre A, Keating M, Cork A, Trujillo JM, et al. Molecular heterogeneity in acute leukemia lineage switch. *Blood.* 1989; 74(6):2088-95. PubMed PMID: 2553159.
10. Dorantes-Acosta E, Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity? *Bone Marrow Res.* 2012; 2012:406796. doi: 10.1155/2012/406796. PubMed PMID: 22852088. PubMed Central PMCID: PMC3407598.



LETTER TO EDITOR

Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia

Babak Abdolkarim*

Assistant Professor of Pediatric Department, Lorestan University of Medical Science, Khoramabad, Iran

ARTICLE INFO

Article History:

Received: 13.06.2016

Accepted: 27.07.2016

*Corresponding author:

Babak Abdolkarimi, MD

Address: Shahid Madani hospital,
Lorestan University of Medical
Science, Khoramabad, Iran

Tel: +98 918 3605274

Email: b.abdolkarimi@yahoo.com

Please cite this article as: Abdolkarimi B. Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia. IJBC 2016; 8(3): 88-89.

Dear Editor

Growing evidence indicates that the innate and adaptive immune system has an important role in both development and treatment of cancer. The concept of metronomics therapy and mechanism of chemotherapeutic agents during maintenance phase of acute lymphoblastic leukemia (ALL) is an obscure topic for oncologists compared with treatment of other phases of this malignancy.

Some new immunological mechanisms have been proposed for the treatment of ALL during the maintenance phase of chemotherapy in addition to traditional irradiation mechanisms. Using regular continuous low-dose chemotherapeutic drugs during the maintenance phase is similar to metronomic strategy that may restore or mediate anticancer immune responses or antiangiogenic effects.¹ Anti-pyrimidines (6-mercaptopurine or 6-thioguanine), dexamethasone or prednisone, oral methotrexate and vincristine are standard approaches in maintenance therapy of ALL.

Malignant cells can escape from immune surveillance in different phases of tumor interaction with the host's immune system. Regulatory T cells (Treg) are CD4⁺ CD25⁺ lymphocytes, enriched in FoxP3, glucocorticoid-induced TNF receptor and cytotoxic T-lymphocyte-associated antigen-4 that can inhibit antigen-specific immune response both in a cytokine-dependent and cell contact-dependent method.² Treg cells can inhibit

anti-tumor immune response by suppressing the activity of both tumor-specific effector cells (CD8⁺ cytotoxic T lymphocytes and CD4⁺ T helper cells) and tumor-nonspecific effector cells (natural killer [NK] and NK T cells).¹ Also, Treg cells have been shown to be increased in a variety of human cancers. Increased frequency of Treg cells is associated with tumor progression and loss of treatment response.³ Moreover, suppression of Treg cell activity by either specific blockade or depletion of them can enhance immune response against tumor-associated antigens.¹

During the last decade novel mechanisms has been found for methotrexate in the treatment of rheumatoid arthritis. It restores defective Treg cell function through demethylation of the FOXP3 locus, leading to subsequent increase in FoxP3 and CTLA-4 expression.⁴ Dexamethasone improves the function of regulatory T-cells and sets up a new balance of Th1/Th2 that markedly enhances FOXP3 expression and generates CD25(high) cells with phenotypic characteristics attributable to natural Treg cells.⁵

6-Thioguanine inhibits different steps of the angiogenesis process in vitro and uses a potent anti-angiogenic activity in vivo. Its anti-angiogenic ability together with its antimetabolite activity towards tumor cells may contribute to its action during maintenance therapy in acute myeloid leukemia (AML). These results

suggest a new rationale for the use of purine analogs in the management of AML.^{6,7}

6-mercaptopurine (6-MP) specifically inhibits both the early and the late phases of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in vivo.⁶ Vincristine also suppresses angiogenesis and the anti-angiogenic activity may be enhanced by combination with 6-TG.⁸

In summary we consider low dose continuous conventional chemotherapy as a metronomic mechanism of action with induction of antitumor immune response and antiangiogenic effects in ALL patients. This hypothesis needs to be more investigated specially in pediatric ALL.

Acknowledgment

I would like to thank Dr Nicolas Andre, Associate Professor in the Department of Pediatric Oncology and Hematology in the “Hôpital pour Enfants de La Timone”, AP-HM, in Marseille and in the Faculty of Medicine, Aix-Marseille” University, France, for his valuable guides.

Conflict of Interest: None declared.

References

1. Cooper SL, Brown PA. Treatment of Pediatric Acute Lymphoblastic Leukemia. *Pediatr Clin North Am.* 2015; 62(1): 61–73. doi: 10.1016/j.pcl.2014.09.006. PubMed Central PMCID: PMC4366417.
2. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. *Arch Immunol Ther Exp (Warsz).* 2008; 56(3):181-91. doi: 10.1007/s00005-008-0018-1. PubMed PMID: 18512029.
3. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. *Cancer Immunol Immunother.* 2006; 55(9):1064-71. doi:10.1007/s00262-005-0092-8. PubMed PMID: 16328385.
4. Cribbs AP, Kennedy A, Penn H, Amjadi P, Green P, Read JE, et al. Methotrexate restores regulatory T Cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. *Arthritis Rheumatol.* 2015; 67(5):1182-92. doi: 10.1002/art.39031. PubMed PMID: 25604080.
5. Hu Y, Tian W, Zhang LL, Liu H, Yin GP, He BS, et al. Function of regulatory T-cells improved by dexamethasone in Graves' disease. *Eur J Endocrinol.* 2012; 166(4):641-6. doi: 10.1530/EJE-11-0879. PubMed PMID: 22219499.
6. Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M, Ribatti D. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. *Cancer Res.* 1999; 59(10):2417-24. PubMed PMID: 10344752.
7. Presta M, Belleri M, Vacca A, Ribatti D. Anti-angiogenic activity of the purine analog 6-thioguanine. *Leukemia.* 2002; 16(8):1490-9. doi: 10.1038/sj.leu.2402646. PubMed PMID: 12145690.
8. Yang J, Jiang M, Zhen YS. Novobiocin inhibits angiogenesis and shows synergistic effect with vincristine. *Yao Xue Xue Bao.* 2003; 38(10):731-4. PubMed PMID: 14730893.



PHOTO CLINIC

Portal Vein Thrombosis Following Splenectomy in β -thalassemia Major

Sara Sadeghi^{1*}, Ahmad Mohammadi Ashiani¹, Mitra Khalili²

¹Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Pediatric Radiology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 29.05.2016

Accepted: 01.07.2016

*Corresponding author:

Sara Sadeghi,
Pediatric Congenital Hematologic
Disorders Research Center, Shahid
Beheshti University of Medical
Sciences, Tehran, Iran
Email: sadeghisaramd@gmail.com

Please cite this article as: Sadeghi S, Mohammadi Ashiani A, Khalili M. Portal Vein Thrombosis Following Splenectomy in β -thalassemia Major. IJBC 2016; 8(3): 90-91.

A 25-year-old man with thalassemia major underwent cholecystectomy and splenectomy due to persistent colicky abdominal pain and increased blood requirements. He was febrile during the week after splenectomy, so that a thoraco-abdominal CT scan was scheduled for the patient which revealed evidence of thrombosis in main portal vein, superior mesenteric vein and splenic vein. Ultrasound color Doppler confirmed extensive area of thrombosis in portal vein. MRV images did not show any flow in portal and splenic veins (figure 1).

Thromboembolic (TE) events have been frequently reported in β -thalassemic patients along with risk factors such as diabetes, cardiopulmonary dysfunction, hypothyroidism, liver function abnormalities and post splenectomy thrombocytosis.¹ Although a high prevalence of thromboembolic events in thalassemia intermedia, particularly in splenectomized patients has been reported (29%),² incidence of TEs has been reported to be from 1.1-5.3% in thalassemia major patients in different studies.¹

Portal vein thrombosis is a well-known complication following splenectomy in beta thalassemia major.¹ Female gender, decreased levels of coagulation inhibitors, thrombocytosis and huge splenomegaly are predisposing factors for developing portal vein thrombosis. However, it is recommended that Doppler ultrasonography be performed in all patients after splenectomy to screen portal vein thrombosis.¹ We suggest that prophylactic




Figure 1: MRV images shows evidence of lack of flow in portal venous system. Abdominal CT-scan shows extensive thromboses in portal, mesenteric and splenic veins with cavernous transformation.

antiplatelet and antithrombotic therapy be considered in all thalassemic patients even before splenectomy.

Conflict of Interest: None declared.

References

1. Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. *Acta haematologica*. 1998;99(2):76-9.
2. Cappellini M, Robbiolo L, Bottasso B, Coppola R, Fiorelli G. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. *British journal of haematology*. 2000;111(2):467-73.
3. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood*. 2002;99(1):36-43.
4. Soyer T, Ciftci AO, Tanyel FC, Şenocak ME, Büyükpamukçu N. Portal vein thrombosis after splenectomy in pediatric hematologic disease: risk factors, clinical features, and outcome. *Journal of pediatric surgery*. 2006;41(11):1899-902.